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PREFACE
Note to the reader:
Chapters 2-6 of this dissertation were originally written individually for
publication in peer reviewed scientific journals, and while much has been added to
tie the chapters together as a single cohesive document, they were originally
intended as stand-alone manuscripts. At the time of submission, Chapters 2, 3 and 5
have been accepted for publication while Chapter 4 is currently in the second round
of the review process in the journal Medical Dosimetry and the manuscript from
Chapter 6 is intended to be submitted to the International Journal of Radiation
Oncology Biology and Physics.
Chapter 2 was originally published in Medical Physics (2013) under the title
“Dosimetric comparison of helical tomotherapy treatment plans for total marrow
irradiation created using GPU and CPU dose calculation engines.” Chapter 3 was
originally published in Medical Dosimetry (2016) under the title “Dosimetric
evaluation of total marrow irradiation using 2 different planning systems.” Chapter 5
was originally published in the Journal of Applied Clinical Medical Physics (2017)
under the title “Single fraction radiosurgery/stereotactic body radiation therapy
(SBRT) for spine metastasis: A dosimetric comparison of multiple delivery
platforms”.

iv

TABLE OF CONTENTS
Dedication................................................................................................................... ii
Acknowledgments ..................................................................................................... iii
Preface ...................................................................................................................... iv
List of Tables ........................................................................................................... viii
List of Figures ............................................................................................................ ix
List of Abbreviations .................................................................................................. xi
Chapter 1 “Overview” .................................................................................................1
1. Introduction ........................................................................................................1
1.1 Radiation Therapy .........................................................................................1
1.1.1 IMRT Delivery Techniques .....................................................................2
1.1.2 IMRT Optimization .................................................................................5
1.1.3 Dose Calculation ....................................................................................6
1.1.4 Prescription Dose and Fractionation ......................................................7
1.2 Statement of the Problem .............................................................................9
Chapter 2 “GPU and CPU Based Dose Calculation Algorithms” ..............................12
2.1 Introduction .................................................................................................12
2.2 Methods and Materials ................................................................................13
2.3 Results ........................................................................................................17
2.4 Discussion ..................................................................................................19
2.5 Conclusions ................................................................................................22
Chapter 3 “Dosimetric Evaluation of Total Marrow Irradiation Using Two Different
Planning Systems” ....................................................................................................23

v

3.1 Introduction .................................................................................................23
3.2 Methods and Materials ................................................................................24
3.2.1 Phantom and contouring ......................................................................24
3.2.2 Modality and plan objectives ................................................................25
3.2.3 TomoTherapy planning ........................................................................25
3.2.4 Eclipse planning ...................................................................................26
3.3 Results ........................................................................................................30
3.3.1 PTV analysis ........................................................................................30
3.3.2 OAR sparing ........................................................................................31
3.3.3 Treatment planning time ......................................................................33
3.3.4 Beam-on time.......................................................................................34
3.4 Discussion ..................................................................................................34
3.5 Conclusions ................................................................................................37
Chapter 4 “Total Marrow Irradiation: A Comprehensive Approach to Treatment
Planning for Helical Tomotherapy” ...........................................................................38
4.1 Introduction .................................................................................................38
4.2 Methods and Materials ................................................................................39
4.3 Results ........................................................................................................43
4.3.1 Field width ............................................................................................43
4.3.2 Pitch .....................................................................................................44
4.3.3 Modulation factor .................................................................................46
4.3.4 Beam delivery time ..............................................................................47
4.3.5 Plan quality index Q .............................................................................47
4.4 Discussion ..................................................................................................49
vi

4.5 Conclusions ................................................................................................51
Chapter 5 “Single Fraction Radiosurgery/Stereotactic Body Radiation Therapy
(SBRT) for Spine Metastasis: A Dosimetric Comparison of Multiple Delivery
Platforms” .................................................................................................................52
5.1 Introduction .................................................................................................52
5.2 Methods and Materials ................................................................................54
5.3 Results ........................................................................................................57
5.4 Discussion ..................................................................................................63
5.5 Conclusions ................................................................................................65
Chapter 6 “Analysis of Dose Fractionation Regimens for Total Body Irradiation
Based on Interstitial Pneumonitis Risk Factors” .......................................................67
6.1 Introduction .................................................................................................67
6.2 Methods and Materials ................................................................................68
6.3 Results ........................................................................................................73
6.4 Discussion ..................................................................................................76
6.5 Conclusions ................................................................................................80
Chapter 7 “Conclusion” .............................................................................................82
7.1 Summary of findings ...................................................................................82
References ...............................................................................................................87
Abstract ..................................................................................................................106
Autobiographical Statement ...................................................................................110

vii

LIST OF TABLES
Table 1. Summary of plan parameters. *PTV1 - skeletal bone only, PTV2 - 5 mm
expansion, PTV3 - 5 mm expansion on Ribs and Femurs only ................ 16
Table 2. Difference in dose relative to 12 Gy. Formula: (GPU-CPU)*100/12Gy. ... 18
Table 3. Gamma Γ(3%, 3mm)<1 analysis results. ................................................. 18
Table 4. Optimization/dose calculation time. .......................................................... 19
Table 5. Dose to PTV, in cGy. ................................................................................ 31
Table 6. OAR doses in cGy. Difference shown as (Eclipse-Tomo)/Eclipse. .......... 32
Table 7. Machine optimization parameters. ............................................................ 41
Table 8. PTV and OARs constraints. ...................................................................... 42
Table 9. Average beam on times across all targets for each modality. ................... 62
Table 10. Range of parameters used in the analysis. ............................................. 72
Table 11. Cox logistic regression results for model I. ............................................ 74
Table 12. Cox logistic regression results for model II. ........................................... 74

viii

LIST OF FIGURES
Figure 1. A schematic of the "rib problem". Both images show a RapidArc beam at
two different gantry angles. Although zero collimator rotation (1a) appears
to have good coverage, it is too narrow to allow any "tangential" beamlets
to the ribs. Any dose to the ribs must also pass through the lungs. Image
(1b) is an example of 90° collimator angle, showing how the much wider
beam provides excellent access to tangential beamlets through the ribs,
which avoid the lungs. .............................................................................. 29
Figure 2. Eight arcs shown in three configurations. a) with a collimator rotation of
90°, showing lack of overlap with adjacent fields, b) with a collimator
rotation of 45°, showing both good coverage and good overlap. (Note that
the white areas of the body are fully covered as the arcs rotate around the
body.) c) with a 90° collimator, but with the beams moved asymmetrically
(fields are shown offset left and right for clarity)........................................ 29
Figure 3. Doses to PTV, Lung and Small Bowel. .................................................... 30
Figure 4. Heart and Brain DVHs. ............................................................................ 31
Figure 5. Kidney and Liver DHVs. .......................................................................... 32
Figure 6. Relative dose difference between FW 2.5 and 5.0cm. Pitch 0.43 & 1.5 MF
.................................................................................................................. 43
Figure 7. Relative dose difference between FW 2.5 and 5.0cm. Pitch 0.287 &2.5 MF.
.................................................................................................................. 44
Figure 8. Relative dose difference between pitch 0.287, 0.43 & 0.86. FW 2.5, 2.5MF.
.................................................................................................................. 45
Figure 9. Relative dose difference between pitch 0.287. 0.43 & 0.86. FW 5.0, 1.5MF.
.................................................................................................................. 45
Figure 10. Relative dose difference as a function of MF. FW 2.5, Pitch 0.287. ...... 46
Figure 11. Relative dose difference as a function of MF. FW 5.0, Pitch 0.287. ...... 47
Figure 12. Beam on time as a function of MF. ........................................................ 48
Figure 13. Plan quality summary. ........................................................................... 48
Figure 14. Axial representations of target volumes (Red) and spinal cord (Green)
along with sagittal image of target “D” to illustrate its extent across two
vertebral levels. ......................................................................................... 55
ix

Figure 15. Lumbar Target A.................................................................................... 58
Figure 16. Lumbar Target B.................................................................................... 58
Figure 17. Lumbar Target C. .................................................................................. 59
Figure 18. Lumbar Target D. .................................................................................. 59
Figure 19. Thorax Target A..................................................................................... 60
Figure 20. Thorax Target B..................................................................................... 60
Figure 21. Thorax Target C. ................................................................................... 61
Figure 22. Thorax Target D. ................................................................................... 61
Figure 23. Isodose distribution for Targets B and C (Red) and their relationship with
the spinal cord (Purple). Isodose line are as follows: 16.8 Gy – Orange;
16.0 Gy – Black; 14.4 Gy – Green; 12.0 Gy – Light Blue; 8.0 Gy – Dark
Blue. ......................................................................................................... 62
Figure 24. Frequency and type of chemotherapy used. .......................................... 70
Figure 25. Radiation prescription histogram. .......................................................... 71
Figure 26. Dose per fraction histogram. ................................................................. 71
Figure 27. Lung EQD2_repair response function for all fractionation schemes. ..... 75
Figure 28. Lung EQD2_repair response function for multiple fraction per day
schemes. .................................................................................................. 76

x

LIST OF ABBREVIATIONS
3DCRT……………………………….……3 Dimensional Conformal Radiation Therapy
2D……………………………………………..……………………………….2 Dimensional
AAA ……………………………………..………………..Analytical Anisotropic Algorithm
AP ……………………………………………………………………….. Anterior-Posterior
BMT ………………………………………………..……………..Bone Marrow Transplant
CCCS……………………………………. Collapsed-Cone Convolution/Superposition
CK ……………………………………………………………………………….. CyberKnife
CPU …………………………………………………….………… Central Processing Unit
CT ………………………………………………………………… Computed Tomography
Cy …………………………………………………………...…………..Cyclophosphamide
D”xx” ………………………………………………….……………Dose to xx% of Volume
DCS ……………………………………………………..……………..Dose Control Servo
DVH ………………………………………………………..……. Dose Volume Histogram
FFF …………………………………………………………...……… Flattening Filter Free
FW ………………………………………………………………………………. Field Width
GB …………………………………………………………………………………. Gigabyte
GPU …………...………………………………………………….Graphic Processing Unit
GVHD ………………..……………………………………………. Graft vs. Host Disease
HDMLC …………………….……………………….High Definition Multi Leaf Collimator
HT ……………………………………………………………………..Helical Tomotherapy
HVL…………………………………………………………………..……..Half Value Layer
IMAT……………………………………………………..Intensity Modulated Arc Therapy
xi

IMRT ……………………………………………. Intensity Modulated Radiation Therapy
IP ……………………………..……………………………………. Interstitial Pneumonitis
LPC………………………………………………………Lethal Pulmonary Complication
LQ …………………………………..…………………………………….. Linear Quadratic
MC…………………………………………………………………….…………Monte Carlo
MF ………………………………………...…………………………….. Modulation Factor
MLC ………………………………...…………………………………Multi Leaf Collimator
MRI ……………………………..…………………………. Magnetic Resonance Imagine
MU ……………………………………….…………………………………… Monitor Units
MVA…………………………………………………..………………. Multivariate Analysis
NVBB …………………………………………….……….. NonVoxel-based Broad-Beam
OAR ………………………………………………………………………......Organ at Risk
OR………………………………………………………………………...………Odds Ratio
PA …………………………………………………………………………Posterior-Anterior
PGI …………………………….…………………………… Paddick dose Gradient Index
PTV…………………………………..……………………………Planning Target Volume
QA ……………………………………….……………………………….Quality Assurance
RTOG……………………………………….………. Radiation Therapy Oncology Group
SBRT ……………………………..………………. Stereotactic Body Radiation Therapy
SRS ……………………………………………………………..Stereotactic Radiosurgery
TB …………………………………………………………………………………TrueBeam
TBI ……………………………………………………………………Total Body Irradiation
TMI ……………………………………………….………………. Total Marrow Irradiation
xii

TPS ……………………………………………..…………….Treatment Planning System
V”xx” …………………………….……………………………Volume Receiving “xx” dose
VMAT ……………………………………..………….Volumetric Modulated Arc Therapy
VoLO ……………………………………….……………………..Voxel-Less Optimization
VP-16 …………………………………………………………………………….. Etoposide

xiii

1

CHAPTER 1 “OVERVIEW”
1.

Introduction
Cancer is the second most common cause of death in the United States,

surpassed only by heart disease, and accounts for nearly 1 of every 4 deaths. In
2016 there were approximately 1.7 million new cancer cases diagnosed and about
600 thousand deaths from this disease in the United States alone1.

Treatment

options depend on type, location and stage of the cancer and may involve radiation
therapy, chemotherapy, surgery, hormonal therapy and/or targeted therapy. With
about half of all cancer patient receiving radiation therapy, it plays an important role
in the treatment of cancer and can be used with a curative intent or as a palliative
treatment to alleviate pain or symptoms. Due to a combination of improvements in
early diagnosis and treatment techniques, the 5 year relative survival has been
steadily increasing over the last few decades. However, there is still much room for
improvement in both survival and patient quality of life, and potential future
improvements from radiation therapy will depend on our ability to better apply and to
improve our technology and treatment techniques.

This thesis investigates the

potential improvements possible for a subset of these radiation therapy treatment
techniques.
1.1

Radiation Therapy
Shortly after the discovery of radioactivity by Maria Skłodowska Curie, and its

ability to kill cancer cells, the first patient was treated with external beam radiation
therapy.

The applications of radiation to the treatment of tumors have evolved

tremendously ever since. Some of the technical innovations include the use of

60
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for teletherapy, followed by the much more complex electron linear accelerator in the
pursuit of higher energy beams for the ability to treat deep seated tumors.
Advances in computer technology in the 1970’s and the invention of computed
tomography (CT), made it possible to image the patient and map the tumor and
surrounding healthy tissue in 3 dimensions (3D). At the same time, improvements in
beam collimation led to the introduction of 3D conformal radiation therapy (3DCRT).
With the detailed knowledge of the shape and position of the tumor, it was now
possible to conform the spatial distribution of the prescription dose to the 3D target
volume, while minimizing the dose to the surrounding healthy organs. The delivery
of 3DCRT is typically accomplished with a set of radiation beams positioned at fixed
gantry angles, which are shaped using a beams eye view of the target volume. The
intensity of the radiation beams is usually uniform across the field or may be altered
by simple fluence modifying devices such as wedges or compensators.
Subsequently, the introduction of the multi-leaf collimator (MLC),2 largely replacing
cast blocks for beam shaping, and advancements in dose calculation algorithms, led
to the introduction of intensity modulated radiation therapy (IMRT).
1.1.1 IMRT Delivery Techniques
Intensity modulated radiation therapy is based on the use of optimized non
uniform radiation beam intensities to deliver highly conformal and uniform dose to
the target volume while minimizing dose to adjacent normal tissue. Historically, the
beam fluence modulation was achieved by compensators, which varied in thickness
across the plane perpendicular to the central axis. The limitations of compensators
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included limited dynamic range of fluence modulation as well as time consuming and
laborious fabrication of these patient specific devices.
The first clinical MLC system was the MIMiC collimator which was mounted
on a conventional linear accelerator as a tertiary collimator.

The beam was

collimated to a narrow (~ 2cm) slice and the gantry was rotated about the patient in
an arc mode.

The binary leaves were temporally modulated to vary the beam

intensity as a function of gantry angle. Typical treatment consisted of delivering
several adjacent axial slices.

Due to the serial nature of this delivery, extreme

accuracy of couch positioning was incredibly important. Couch positioning errors of
as little as 1 mm could cause dose errors as high as 20% in the overlap region.3-4
This approach was initially called tomotherapy which literally means slice therapy,
but subsequently renamed serial tomotherapy.
The “Tomotherapy” device proposed by Mackie et al.5-6 used a similar binary
collimator but delivers helical tomotherapy. The Tomotherapy machine consists of
6MV linear accelerator mounted on a ring gantry that rotates around the patient
while the patient is translated through the bore at constant speed effectively creating
a helical path of radiation delivery. The beam is collimated by 64 binary leaves with
a width of 6.25 mm projected at isocenter, forming a maximum field size in the
lateral direction of 40 cm. The leaves are pneumatically driven to either open or
closed position through 51 “projections” (approximately 7 degrees) of the gantry
rotation and beam modulation is achieved by varying the time that each leaf is open
during a projection. For the inferior-superior direction, a movable set of tungsten
jaws collimates the width of the fan beam slice to nominal values of 1, 2.5 and 5 cm
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wide.

More recent models of Tomotherapy machines provide dynamic jaw

movement, which allows the jaws to move to any position between 0 and 5cm and
move during the treatment.

Details of this functionality have been described

previously by Chen et al.7
Another common technique to produce intensity modulated beam is by the
use of the conventional MLC. This type of MLC has a set of leaves on each side of
the field creating opposing leaf pairs. The design and shape of the leaves may vary
from machine to machine, but the principal functions are the same. Each pair of
opposing leaves is moved across the field under computer control, with the radiation
beam on, to produce desired beam modulation. This type of delivery is termed
dynamic or sliding window. Alternatively, beam modulation can be accomplished by
a series of multiple field segments, called subfields, created by the MLC. The beam
is turned off during the leaf motion between the individual subfields. This method is
known as step-and-shoot or segmental IMRT delivery. Another conventional MLC
IMRT approach, called intensity modulated arc therapy (IMAT), was described by Yu
et al.8-10 Beam modulation in this approach is achieved by multiple irregular fields
shaped by the MLC during gantry rotation.

This method required several

overlapping arcs to attain desired dose distribution. Otto et al.11 proposed a novel
aperture-based algorithm to achieve efficient dose delivery in singe dynamically
modulated arc as opposed to multiple superimposed arcs as in IMAT to achieve
similar dose distribution with reduced treatment time.

This technique has been

termed Volumetric Modulated Arc Therapy (VMAT).

VMAT delivery employs

continuously variable MLC field shape, fluence rate and gantry speed.

5

Finally, an intensity modulated dose distribution can be created by the
delivery of multiple individual beamlets. This method was described by Webb12-13
and is commonly employed using a small x-band linear accelerator mounted on an
industrial robot. The beamlet sizes are dependent on the collimation system and
can range from 5 to 60 mm in diameter and can be circular or 12-sided polygon.
This type of robotic delivery using a small accelerator allows beamlets to be aimed
at the tumor from any orientation giving this IMRT delivery method more flexibility
than any of those previously discussed.
1.1.2 IMRT Optimization
All the IMRT delivery techniques described above have in common the ability
to deliver non-uniform fluence patterns which add up to desired conformal dose
distributions.

Regardless of the of delivery technique, the optimization of such

fluence patterns requires significant computational power and is performed using a
computerized treatment planning system (TPS). The TPS must be able to create a
plan which meets the goals of the clinician and these goals are commonly conveyed
to the treatment planning system as goals or constraints which the TPS attempts to
meet through a process called inverse treatment planning. Historically, planning for
3DCRT was performed in forward planning manner, where beam shape is defined
by the planner, the dose is calculated and the resulting plan is then evaluated for
target dose coverage and organs at risk (OAR) dose limits. Improvements to the
plan are then performed by changing the geometry of the beam and/or adding beam
modifiers and new dose distribution is calculated. The process continues until a
satisfactory plan is generated. In inverse treatment planning, the planner specifies
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the desired outcome and asks the TPS figure out how to achieve that goal. The
clinical objectives are commonly specified mathematically in the form of a cost
function. The optimization algorithm iteratively adjusts the intensities of all available
beamlets to minimize the cost function in an attempt to satisfy the constraints set by
the planner. Most IMRT optimization systems use dose-volume based criteria and
commonly use the cost function to minimize the variance between the computed
dose and the desired dose for each target volume and Organ at Risk (OAR). A
typical cost function is the sum of the variances for each target and OAR multiplied
by penalty or weighting factor based on the assigned importance of that structure.
During IMRT optimization, the dose distribution from each iteration is
evaluated and used to calculate the cost function before the next iteration can be
initiated. Typical treatment plan requires hundreds (for gradient method) to tens of
thousands (for stochastic method) of iterations to achieve an acceptable results,
therefore the speed of dose calculation algorithm is extremely important. Besides
the speed, the algorithm must also be able to accurately calculate dose in regions of
complex tissue heterogeneities delivered by conformal beams consisting or small
beamlets forming steep dose gradients.
1.1.3 Dose Calculation
Correction based dose calculation algorithms14-15 do not account for electron
contamination, transmission through the jaws and MLC, scatter outside the field,
finite source size and extrafocal radiation generated by the primary collimator. These
algorithms also lack accuracy in heterogeneous media and are unsuitable for use in
IMRT dose calculations.

More recent, commercially available dose calculation
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algorithms that address some of the limitations of the correction based algorithms
can be divided into two categories: model based and Monte Carlo (MC) based.
These dose calculation methods are not perfect and still exhibit some limitations in
accuracy and/or calculation speed, however they have been routinely used in IMRT
treatment planning. In order to improve calculation speed without compromising
accuracy, several attempts have been made to modify the existing calculation
models while leveraging advancements in computing power. In 2011, Chen et al.
presented a novel algorithm for computing collapsed-cone convolution/superposition
(CCCS) dose on modern graphic processing unit (GPU).16 Results from validation
and clinical application of this algorithm are presented in chapter 2 of this
dissertation.
1.1.4 Prescription Dose and Fractionation
The mechanical accuracy of external beam therapy machines has improved
dramatically and sub-millimeter targeting is now achievable.

This presents new

challenges as well as new opportunities. For example, the opportunity to see the
tumor immediately prior to treatment and treat it with high conformity is accompanied
by the risk of missing the target due to patient or tumor motion.

Once these

challenges are addressed, delivering highly conformal dose to the target volume will
result in lower doses to the surrounding healthy organs and lower toxicities.
Subsequently, the prescription dose, which is usually limited by the OAR toxicities
can be escalated and potentially offer higher tumor control probability.
Increasing prescription doses is also possible through fractionation. Healthy,
normal tissues and OAR are considered late-reacting tissue cells and have higher
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propensity for repair than do tumor cells. By fractionating the prescription dose and
allowing sufficient time between the fractions for sublethal cell damage repair, the
healthy tissues will have a higher surviving fraction than the tumor. Historically, the
most common fractionation scheme was in 1.8 Gy – 2.0 Gy fractions delivered once
a day. The daily separation between the fractions made it not only convenient, but
also allowed sufficient time for cell damage repair. The fraction size of 1.8 - 2.0 Gy
was derived from cell survival curves displaying greatest separation between tumor
and late-reacting normal tissue cells.
Not all tumors and healthy tissues have the same cell repair characteristics.
The fractionation sensitivity parameter, α/β, ranges for tumors and healthy tissues
from 5 Gy to 20 Gy and from 1 Gy to 4 Gy, respectively. Due to the vast range of
these values, different fractionation schemes have been proposed and studied.
Some healthy tissues have very low α/β values and conventional fractional doses
may not provide optimal therapeutic benefit, thus a hyperfractionated scheme may
be warranted. In this scheme, low doses of 1.0 Gy to 1.5 Gy are delivered twice or
even three times a day for a total dose that is higher than in conventional
fractionation regimen. The situation is the opposite for tumors with low α/β ratios, in
which case hypofractionation may be desirable.

Patients treated with this

fractionation regimen receive lower prescription dose delivered in a smaller number
of large fractions typically separated by 2 or more days.

All the fractionation

schemes depend on the accurate knowledge of the α/β ratios, and their efficacy can
only be confirmed by clinical trials.
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1.2

Statement of the Problem
With the advancements in IMRT dose calculation algorithms and treatment

delivery methods it is now possible to apply this new technology to challenging
clinical cases such as total marrow irradiation (TMI) and stereotactic radiosurgery
(SRS).

The conditioning regimen for bone marrow transplantation (BMT) has

historically included irradiation of the bone marrow, and total body irradiation (TBI)
has been employed because the technology was not mature enough to allow
treatment of the bone marrow only. TBI treatments have traditionally been delivered
at extended distances due to radiation field limitations, and dose calculations were
done very simplistically as most commercial planning systems are not designed to
handle such calculations at extended distances. The introduction of Tomotherapy
machine has overcome some of these limitations. The capability of treating up to a
160cm target in the longitudinal direction eliminates the need for treatment at an
extended distance and/or field matching as it would be required when using
conventional C-arm linacs. With IMRT, it is possible to target the marrow and spare
OARs with what is now known as Total Marrow Irradiation (TMI). As would be
expected the very large structures and dose calculation volumes for TMI result in
significantly larger optimization and dose calculation times for the treatment planning
system. This limitation has now been addressed with the introduction of a novel
Graphics Processing Unit (GPU)-based dose calculation and optimization algorithm.
The first stage of this work was to evaluate the accuracy and efficacy of
Tomotherapy’s GPU-based TPS system for the treatment of TMI (Chapter 2) and
further compare the plan quality and planning efficiency with plans created using the
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Varian Eclipse TPS (Varian Medical Systems Inc, Palo Alto, CA) using VMAT
(Chapter 3).
The process of treatment planning for TMI cases is not without significant
challenges. Due to the extremely large target volume, the optimization parameters
routinely used for other clinical sites are not optimal for TMI plans. Some of the
parameters cannot be used to their full extent due to either machine limitations or
treatment plans resulting in excessive beam-on times. To address these challenges,
a comprehensive planning guide for TMI treatments was developed (Chapter 4).
Before the introduction of dynamic jaws, all the Tomotherapy plans resulted in
excessive dose spillage in the superior and inferior direction outside the target
volume. This issue was especially concerning for small targets and targets abutting
critical structures located superiorly or inferiorly to the target. In order to lessen this
effect, smaller filed sizes were typically used, which resulted in improved plans, but
at the expense of longer beam-on time. Dynamic jaws were designed to limit the
dose spillage and improve the beam-on time without sacrificing plan quality. The
goal for this part of the study was to determine whether there are significant
differences in planning and delivery capabilities of Tomotherapy as compared to
other delivery platforms within the context of RTOG 0631 radiosurgery/SBRT trial
(Chapter 5).
Currently there is no consensus on the optimal fractionation and conditioning
regimen for BMT treatments.

Published results from clinical trials show vast

differences in treatment methods. These differences include the use of different
chemotherapy agents, some of which have a synergistic effect with radiation.
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Differences in the TBI component alone include differences in the prescription
doses, number of fractions used, frequency of radiation delivery, dose rates, and
amount and method of lung shielding. The final goal of this research was to evaluate
historical published data and, through the use of current radiobiological data and
modeling, propose new fractionation schemes for TBI/TMI treatments that may be
expected to be clinically and/or logistically superior to current schemes (Chapter 6).
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CHAPTER 2 “GPU AND CPU BASED DOSE CALCULATION ALGORITHMS”
2.1

Introduction
Bone marrow transplantation (BMT) is commonly accompanied with

radiotherapy in the form of total body irradiation (TBI). The TBI serves as a
conditioning regimen and helps with immunosuppression in patients undergoing
hematopoietic cell transplantation17.

Previous randomized trials have shown

excellent outcome using TBI as a conditioning regimen18-20. Higher TBI doses of
15.75Gy have also been shown to reduce post-transplant relapse rates in patients
with chronic and acute myeloid leukemia21-22. However, higher doses did not
improve overall survival due to increased incidence of Graft vs. Host Disease
(GVHD) and excessive toxicity to organs at risk (OAR) such as lung and liver at
these dose levels.
With the advancement of intensity modulated radiation therapy (IMRT) it is
now possible to deliver a more targeted form of total body irradiation termed total
marrow irradiation (TMI). Several institutions have published feasibility studies using
fixed angle IMRT23, Volumetric Modulated Arc Therapy (VMAT)24-27 and Helical
Tomotherapy (HT)28-31 techniques. The objective of the different approaches is to
deliver the prescription dose to the target volume and spare normal organs. All
three IMRT methods were able to deliver the prescription dose while reducing doses
to OARs by ~30% to 80%23-31.
Each delivery technique has some disadvantages. Fixed angle IMRT and
VMAT techniques require multiple isocenters to cover the entire treatment volume.
Each isocenter may require 7-9 static fields or 2-3 arcs for IMRT and VMAT
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respectively to achieve adequate coverage and OAR sparing. The patient has to be
repositioned for each isocenter which may compromise intended dose distribution in
the area of field overlap. Helical delivery is well suited for treatment of longitudinally
large fields since field matching in critical areas is eliminated. The additional time
required for patient repositioning on C-arm linac based systems adds to total
treatment time, although the beam on time for VMAT is much shorter as compared
to HT27. A common weakness for all three planning techniques is the optimization
and dose computation time. Han at al.27 reported planning times of about 5 hours
for eight arc VMAT plans using an Eclipse v8.6 (Varian Medical Systems Inc, Palo
Alto, CA) planning station using 8 Intel Xeon CPUs at 2.5Ghz with 4 GB of memory.
The planning time from our TMI study on the TomoTherapy (Accuray Inc,
Sunnyvale, CA) Hi-Art v4.2 CPU station was about 10 hours utilizing 14 nodes of
quad core Intel Xeon CPUs at 2.8 GHz with 2GB of memory.
Recently, Lu32 has developed a non-voxel-based broad-beam (NVBB)
framework for optimization and dose calculation.

This system has been

incorporated in the TomoTherapy planning system utilizing a single workstation with
one graphical processing unit (GPU) card.

In this study, we compared TMI

treatment plans between CPU and GPU systems in terms of plan quality and total
calculation and optimization time.
2.2

Methods and Materials
In this study we used an anthropomorphic Rando (The Phantom Laboratory,

Salem, NY) phantom to create TMI treatment plans with CPU and GPU based dose
calculation engines.

The computed tomography (CT) images of the phantom were
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acquired on a large bore Somatom Sensation CT simulator (Siemens, Malvern, PA)
with 60 cm field of view. A CT scan was acquired with 5mm slice thickness of the
entire phantom which does not include upper extremities and ends inferiorly in the
mid-femur region. Since the phantom does not have arms, two acrylic cylinders
filled with water were placed on each side of the phantom to mimic the patient’s
arms. In a clinical setting, TMI patients are treated with intensity modulated beams
from the top of the skull to mid femur and the rest of the lower extremities are treated
on a conventional linear accelerator with abutting anterior-posterior (AP) and
posterior-anterior (PA) beams. Treating the entire patient on the Tomotherapy unit
is prohibitive due to the limitation of the machine’s longitudinal couch movement. In
order to complete the treatment on the tomotherapy unit, a second treatment plan
would have to be created with the patient simulated in the feet-first position.
Additional planning, QA, setup and relatively long beam-on-time would be required
for a site that may not benefit from intensity modulation as there are no critical
organs at risk in the lower extremities. Utilizing an AP/PA technique, dose delivery
and calculation is greatly simplified, and the patient is set up such that the superior
border of the lower extremity fields matches the inferior border of the Tomotherapy
treatment. The CT data was exported to Eclipse (Varian Medical System Inc., Palo
Alto, CA) treatment planning system for contouring.
Three different planning target volumes (PTVs) were created. Delineations of
the PTVs were based on experience from centers currently treating total marrow
with intensity modulation28,30,33. PTV1 consisted of all skeletal bone. Since the area
of interest here is the marrow, contouring the bone provides the necessary margins
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for setup uncertainty.

PTV2 included the skeletal bone with additional 5 mm

margins. PTV3 included all skeletal bone with 5 mm margins only on femurs and
ribs. Also, the mandible was excluded from the PTV3 to limit dose to the oral cavity.
The locations of normal organs were approximated by overlaying the images of the
Rando phantom with a template image set.

While several organs at risk were

contoured, only the following five major organs were used in optimization and plan
evaluation: lungs, liver, kidneys, heart and brain. The CT sets along with contours
were then exported to the TomoTherapy Hi-Art v4.2 treatment planning system for
CPU planning and a research treatment planning workstation for GPU planning.
There were five different treatment plans created. The plans differed from
each other not only by the PTV volume chosen for optimization, but also by different
optimization parameters and machine settings.

Among the machine parameters

varied in the planning process were longitudinal field width, pitch and modulation
factor. The user has three options of field width selection: 1 cm, 2.5 cm and 5 cm.
Since the contoured volumes are very large in the longitudinal extent, only 2.5 cm
and 5 cm field widths were evaluated. The pitch is defined as the fraction of the field
width that the treatment couch moves in the longitudinal direction during one gantry
rotation. The pitch was selected to minimize the thread effect34 and provide a good
compromise between plan quality and treatment duration. The initial modulation
factor was chosen to be either 2 or 2.5 which represent typical values used clinically.
The modulation factor is defined as the ratio of the maximal open time of any MLC
leaf to the average leaf opening time for all non-zero leaf opening times. Table 1
lists the key parameters for each of the five plans.
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Plan
Field
Mod.
Actual Mod.
PTV*
#
Width
Pitch
Factor
Factor (CPU, GPU)
Set
1
2.5
0.43
2
(1.761, 1.699)
PTV1
2
5
0.287
2
(1.735, 1.691)
PTV2
3
5
0.287
2
(1.728, 1.677)
PTV1
4
5
0.287
2.5
(2.139, 2.076)
PTV2
5
5
0.287
2.5
(2.176, 2.121)
PTV3
Table 1. Summary of plan parameters. *PTV1 - skeletal bone only, PTV2 - 5 mm
expansion, PTV3 - 5 mm expansion on Ribs and Femurs only

The prescriptions for all plans were set to 12 Gy and “normal” calculation grid
was used for dose calculation. The plans were generated to ensure that 95% of the
PTV received the prescription dose. Several variations of optimization parameters
were used to create the plans. The parameters were set at the beginning of the
optimization and were not adjusted during the optimization process, which consisted
of 100 iterations. This process eliminated user dependency of optimization outcome.
All five plans were optimized and calculated with the same parameters on the CPU
based planning station and the new GPU based research station. The new GPU
system utilizes the TomoHD v136 treatment planning station running on a single
workstation with quad core Intel i7 CPU at 3.07 GHz and NVIDIA GTX470 graphic
card. The details of the GPU based dose calculation algorithm were published
recently by Lu at al.32 and Chen at al.16.
The plans were evaluated based on D50 and D80 (dose to 50% and 80% of
the OAR volume, respectively).

The percentage of target coverage by the

prescription dose is considered a hard constraint in the planning system; therefore
all PTVs received 12 Gy to 95% of their volumes. The PTVs were then assessed
based on V13.2 (volume of PTV receiving at least 13.2 Gy (110% of the

17

prescription)).

A gamma (Γ) analysis35 was performed to compare axial planes

transecting the OARs calculated by each dose engine. The two dimensional dose
distributions were extracted from the plans and exported to RIT software for gamma
analysis (RIT, Colorado Springs, CO).

The dose planes were exported via the

Eclipse (Varian Medical Systems, Palo Alto, CA) planning system where the
matrices were resampled by linear interpolation to 0.5mm resolution. The gamma
analysis represents the percentage of pixels that agreed within 3% dose difference
and/or 3mm distance to agreement. Finally, the planning process for the two dose
engines was evaluated by comparing optimization and dose calculation time as well
as changes in beam-on time duration between the two systems.
2.3

Results
The differences in the OAR doses from CPU based plans and corresponding

GPU based plans were calculated as a percentage of the prescription dose and are
summarized in Table 2. Since all the plans used different machine settings and
optimization parameters the results are presented by evaluating each plan
individually. All D80 and D50 parameters vary by less than 3% of the prescription
dose with an average difference of 0.8%. The differences in V13.2 for the PTVs
were under 3.5% with an average of 1.9% for the five plans. The average dose
values for all the CPU and GPU plans for D50 and D80 are as follows: Lung 7.6Gy
and 6.2Gy, Liver 5.5Gy and 4.6Gy, Kidneys 5.2Gy and 4.6Gy, Heart 5.0Gy and
4.4Gy, Brain 7.2Gy and 3.6 Gy.

The average PTV volume receiving 13.2Gy

between all the plans was 2.6%. The Γ(3%, 3mm)<1 analysis results are presented
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in Table 3. All of the dose planes satisfied the 90% criterion with an average
agreement of 97%.

Plan

V13.2 (%)

D50

D80

D50

D80

Average
Kidneys
D50
D80

D50

D80

D50

D80

1

-0.98

-1.8%

1.3%

0.1%

3.4%

0.5%

0.4%

1.6%

2.9%

-0.4%

1.5%

2

-3.17

-1.4%

-0.9%

0.0%

1.3%

0.1%

0.5%

1.9%

2.3%

-0.1%

0.7%

3

-0.99

-1.0%

-0.9%

-0.3%

1.8%

-0.2%

0.1%

2.2%

2.8%

-0.1%

0.9%

4

-3.43

-2.2%

-1.7%

-0.1%

1.3%

0.1%

0.5%

0.6%

0.5%

-0.1%

0.7%

5

-0.98

-1.5%

0.1%

0.7%

2.4%

0.2%

0.2%

2.7%

2.3%

-0.3%

1.1%

PTV

Lungs

Liver

Heart

Brain

Table 2. Difference in dose relative to 12 Gy. Formula: (GPU-CPU)*100/12Gy.

Plan
#
1
2
3
4
5

Lungs
95.1%
98.5%
98.8%
91.7%
96.1%

Voxels satisfying Gamma Γ(3%, 3mm)<1 GPU vs CPU (%)
Liver
Kidneys
Heart
Brain
93.7%
99.2%
92.3%
96.4%
97.4%
99.1%
97.1%
95.4%
99.1%
99.6%
97.5%
98.8%
97.4%
97.6%
97.1%
98.6%
92.1%
99.9%
95.5%
99.9%

Table 3. Gamma Γ(3%, 3mm)<1 analysis results.

The total optimization and dose calculation times are shown in Table 4. Total
times include beamlet calculation, optimization of 100 iterations, full dose calculation
and final dose calculation for the CPU system. The GPU system does not require
pre-calculation of the beamlets, therefore total time includes optimization of 100
iterations, full dose and final dose calculations. The average time for the CPU based
system was 579 minutes compared to 26.8 minutes for the GPU system.

This

represents greater than a twentyfold reduction in treatment planning time. There
was no difference in calculated delivery times between the two systems. Beam-on
time varied based on field width and pitch and ranged between 15min and 28min.

19

Plan

Beamlet

1
2
3
4
5

468
453
448
471
457

CPU
Optimization
105
120
126
111
83

Optimization/dose calculation time (min)
GPU
Final
Total
Optimization
Final dose
dose
time
12
585
26.0
0.5
9
582
27.3
0.6
11
585
27.0
0.5
9
591
27.4
0.6
12
552
23.5
0.5
Average
579
Average

Total
time
26.5
27.9
27.5
28.0
24.0
26.8

Table 4. Optimization/dose calculation time.

2.4

Discussion
In this study we investigated the plan quality and planning time characteristics

of dose calculation using the new TomoTherapy GPU based dose calculation
system and its application in total marrow irradiation. A recent publication36 has
validated the new GPU system for use with smaller target volumes with excellent
results, however similar studies have not previously been performed for very large
target volumes. There were very small differences in the quality of plans calculated
with the GPU based system as compared to CPU based system. These differences
could be attributed to the gradient descent nature of the optimization algorithms and
fixed number of iterations that may stop the process at a slightly different solution
each time. Gradient descent techniques are relatively fast, but are susceptible to
getting stuck in local minima. Although optimization parameters such as the pitch,
field size, PTV and OAR constraints, numbers of iterations, etc. entered by the
planner were identical for plans calculated in both CPU and GPU based planning
systems, the algorithms are fundamentally different. The CPU system uses voxelbased beamlet-superposition optimization framework whereas GPU system uses
non-voxel-based broad-beam framework, where the objective function and derivative
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are evaluated on continuous view point.

This eliminated time consuming pre-

calculation and storage of beamlets. The details of the algorithms were described
by Lu.32 In addition to the differences in the optimization algorithm, the new GPU
system uses a novel collapsed cone convolution/superposition CCCS algorithm
presented by Chen at al.16 which uses tabulated and exponential kernels and takes
full advantage of the parallel nature of the GPU. This algorithm uses CCCS for
accurate dose calculation for one every ten iterations followed by Fluence-Map
Convolution Broad Beam (FCBB) calculation for the remaining iterations. The FCBB
calculates approximates 3D dose by 2D fluence map convolution with 1D ray
tracing, resulting in orders of magnitude faster calculation than CCCS alone. The
algorithm uses beam’s eye view coordinate system and is also capable of direct
treatment parameter optimization.

These differences in the optimization and

calculation algorithms are most likely the cause for differences in the treatment plan
quality given the same optimization parameters.
This treatment site is likely to benefit the most from the use of the GPU dose
engine since the average computational time is over 9 hours with the current clusterbased CPU system. In centers with only one CPU system, the time consuming
planning of TMI cases can significantly inhibit other clinical work on that system. The
introduction of GPU architecture in the TomoTherapy planning system will make the
transition from conventional TBI to TMI treatments more feasible by preserving
valuable clinical computational resources and providing more flexibility for QA and
patient start times.

The tremendous increase in planning speed provided by GPU
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planning would also be extremely useful for potential future implementation of
adaptive radiotherapy involving on-line replanning.
This study did not investigate the differences in delivery accuracy of the two
systems as the GPU system was dedicated only for research and transferring GPU
plans to our clinical Tomotherapy unit was not possible.

Our prior work on

commissioning TMI using the CPU based system resulted in delivery accuracy
similar to all other clinical cases treated on Tomotherapy. Our QA criteria are +/-3%
for two absolute point dose measurements with small volume ion chambers and
Γ(3%, 3mm)<1 for >90% of points in a film plane dose distribution.
Other groups23-27 have studied the use of IMRT and VMAT for TMI.
Dosimetrically, all of these intensity modulated methods are comparable and offer
significant improvement in normal organ sparing over traditional TBI treatments. All
intensity modulated approaches for treatment of total marrow have some limitations.
With the larger apertures available from a C-arm linac system, the prescription dose
can be delivered using VMAT in about half the time27 it takes HT to deliver the same
dose to a region covered by a single VMAT arc. However, this advantage is lost
when comparing total treatment time and not just beam-on time since the linac
based treatments require several treatment plans to cover the entire target volume.
The patient has to be repositioned for each isocenter, thus prolonging the total
treatment delivery time. Other groups27 have reported limitations on the number of
total arc degrees when using Volumetric Modulated Arc Therapy (VMAT) for large
target volumes. The limitation on total arc degrees will affect the plan quality as only
one arc can be used in a particular section of the PTV in order to cover the entire
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treatment volume. In clinical practice, for other treatment sites, we typically use at
least two full arcs to achieve good plan quality. As mentioned in the methods and
materials section, the portion of the PTV below the mid femurs is treated without
intensity modulation and simple AP-PA treatment is usually sufficient.

Our

Tomotherapy system does not have the capability to treat static beams. Our two
options are to transfer the patient to a C-Arm linac for the remainder of treatment or
reposition the patient to feet-first setup and continue the treatment on Tomotherapy.
Both options add time and uncertainty to the treatment. The former option requires
scheduling and transferring the patient to two machines. The latter option adds
significantly to beam-on time.
2.5

Conclusions
We have presented dosimetric and computational results of the GPU based

TomoTherapy planning system for Total Marrow Irradiation and compared them to
similar results using the traditional CPU system. The agreement of dose distributions
calculated with these two systems using the same targets and optimization
parameters is excellent.

The GPU dose calculation engine overcomes the

significant time constraint limitations that have been associated with creating
treatment plans for large target volumes, as it can calculate the plans in fraction of
time of the traditional CPU system without degradation in plan quality.
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CHAPTER 3. “DOSIMETRIC EVALUATION OF TOTAL MARROW IRRADIATION
USING TWO DIFFERENT PLANNING SYSTEMS”.
3.1

Introduction
Total Marrow Irradiation (TMI) is an advanced version of an existing radiation

therapy treatment method called Total Body Irradiation (TBI). TBI is a radiation
treatment and conditioning regimen used prior to a bone marrow transplant (BMT).3739

Results from previously published randomized trials have demonstrated excellent

outcome from the use of TBI before hematopoietic cell transplants.18-20 Dose
escalation has proven to reduce post-transplant relapse rates with chronic and acute
myeloid leukemia,21,22 however, due to excessive toxicity to OARs, the overall
survival did not improve.
Due to the field size limitations on a standard C-arm linear accelerator at
standard treatment distances, TBI treatments are often delivered at extended
distanced with (anterior-posterior) AP/PA or bilateral techniques. These techniques
traditionally deliver a relatively uniform prescription dose to the entire patient
including all organs at risk (OARs). The exception to this is that for higher doses
and multi-fraction schedules, lung blocks are often used to reduce dose to the lungs.
Lungs are the critical organs at risk, with pneumonitis being a major cause of
complications after TBI treatments. One key study by Volpe, et al.40 established a
threshold mean dose of about 9.4 Gy to the lungs from TBI treatment, beyond which
a significant increase in post BMT mortality exists.
With the advancement of intensity modulated radiation therapy (IMRT) it is
now possible to deliver a therapeutic radiation dose to bone marrow while
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significantly reducing the dose to all healthy organs for patients undergoing
hematopoietic cell transplantation.17,23,25-27,31 However, the attempt to conform the
dose distribution to the marrow only results in a relatively complicated planning
process which is quite dependent upon the particular TPS and delivery method
used. In this study we report quality and efficiency of TMI plans created on two
different treatment planning systems for two different delivery modalities using the
same phantom and structure set.
3.2

Methods and Materials

3.2.1 Phantom and contouring
The patient used for this study was the Rando phantom (The Phantom
Laboratory, Salem, NY), which represents the full human body, except for the
extremities. This anthropomorphic phantom has a human skeleton embedded in
material that mimics soft tissue. There are also air cavities and low density materials
in the lungs to approximate the heterogeneities of a human body.

The Rando

phantom was placed in an immobilization device and simulated in the same manner
as a TMI patient, including a CT scan of the entire length of the phantom with 5mm
slice thickness. As is common in TMI,27 the PTV extended from the most superior
part of the skull to mid-femur. Since there are no critical OARs caudal to mid-femur,
the lower extremities are treated without IMRT using abutting AP/PA fields.
The CT image set was transferred to the Eclipse (Varian Medical Systems Inc, Palo
Alto, CA) TPS for contouring. All bony structures surrounding marrow were included
in the CTV, with the exception of the mandible, which is not a part of marrow forming
skeleton. For the ribs and femurs the PTV was created with 5mm margin. There
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was no margin used for all the other bones because CTV is the bone but the target
is the marrow. The OARs considered in this study and contoured on the CT image
included brain, heart, lungs, liver, kidneys, and small bowel. Since these structures
do not exist in the phantom, they were contoured based on an atlas to approximate
the size, shape and location of the organs in the Rando phantom.
3.2.2 Modality and plan objectives
The Eclipse TPS was used to create a TMI plan using VMAT (Rapid Arc)
delivery on a Varian iX treatment unit. The CT data set and contours were also
exported to the VoLO TPS and used to create a helical tomotherapy treatment plan
on a TomoTherapy Hi-Art treatment unit. The two planning systems use different
optimization schemes and different objective function definitions, which makes it
difficult to set the same planning objectives. Also, the dose delivery methods are
quite different. In RapidArc mode, Varian uses volumetric arcs modulated by MLCs
and stationary couch, whereas TomoTherapy uses helical delivery with binary MLCs
and continuously moving couch. The objectives for both treatment planning systems
were to deliver 1200cGy in 8 fractions to 95% of the PTV and minimize mean dose
and D10 to OARs. Experienced planners created the treatment plans using planning
parameters that are commonly used in our clinic as described below.
3.2.3 TomoTherapy Planning
Tomotherapy delivery for long treatment fields such as TMI is easier than for
conventional C-arm linacs since there is no field matching. The couch movement
through the bore during delivery allows the entire treatment to be delivered in one
session as opposed to the multiple sets of fields required for treatment using
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conventional linacs. As a result, the Tomotherapy planning in this study was much
more straightforward than that for Eclipse.
Many plans were optimized during this study to evaluate the effects of
variations in field width, pitch, and planning modulation factor (MF) necessary to
yield a good plan.

Each of these three parameters had only 2 values, and

represented the most commonly used parameter in our clinic. Field width was either
5 cm or 2.5 cm. Pitch was either 0.287 or 0.430. Modulation factor was either 2.0 or
2.5. The final plan used for this study had parameters of 5cm field width, pitch of
0.287 and modulation factor or 2.5.
3.2.4 Eclipse Planning
The Eclipse portion of the study used Varian Eclipse version 8.9 and was
planned for a Varian iX linac with Millennium 120 Multi-Leaf Collimator (MLC). This
MLC system has 1 cm leaves in the outer portion of the field and 0.5 cm leaves in
the inner 20 cm of the field.

The optimizer in Eclipse was the Progressive

Resolution Optimizer (PRO) version 2, which allowed a total beam angle across all
arcs in one plan of 1500 degrees (just over 4 full arcs).
Initial plans primarily focused on optimizing the full PTV with either three or
four full 360° RapidArc arcs. Each beam had its own isocenter, and the beams were
arranged to overlap each other on the superior/inferior edges. Although some threearc plans were successfully completed, the three overlapping arcs were found to be
insufficient to provide good homogeneity within the PTV. Unfortunately, when 4 full
arcs were used, the software reached the limit of 1500 degrees per plan and with the
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very large PTV size; the computational power needs exceeded what was available in
our workstation.
Due to these existing software and hardware limitations, the single large PTV
was divided into four separate PTV's of roughly equal size. PTV1 covered the head
and neck, PTV2 covered most of the thoracic region, PTV3 covered from about the
top of the liver to mid-abdomen, and PTV4 covered from about mid-abdomen to
about mid-femur.

With the single PTV broken into four sub-PTV’s, it was then

possible to optimize to each PTV individually, thus avoiding the intensive
calculations necessary to optimize the entire body all at once.
Two arcs were used for each sub-PTV with initial isocenter placement in the
middle of each volume along a longitudinal line that would avoid lateral and vertical
patient positioning shifts when going from one isocenter to the next. This approach
used two arcs targeting each sub-PTV, with one rotating counter-clockwise, and the
other rotating clockwise. This double arc set-up produced better plan quality than
using only a single arc. Optimization was typically done first on the PTV2 plan in the
thorax. The dose was calculated and the plan saved. Next, PTV1 was optimized
using the dose from PTV2 as a "base dose" (an Eclipse term).

The base dose is

the final calculated dose distribution from the PTV2 plan which is brought into the
PTV1 optimization and is "seen" by the optimizer as existing dose.

Thus the

optimizer only needs to place dose where no dose already exists, yielding a smooth
junction between PTV's. The process continued like this, optimizing with previous
dose distribution and then calculating the dose for the new PTV. PTV2 was usually
first, followed by PTV1, then PTV3 and finally PTV4. The result of these plans was a
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single plan with eight total beams consisting of four pairs of co-isocentric RapidArc
beams.
Several collimator rotation angles were tested. With the maximum field size
of 40cm in the longitudinal direction and 16cm in the lateral direction (with collimator
at 0°), the degree of collimator rotation had significant implications on PTV coverage
singe the distance between the isocenters was larger than the maximum 16cm field
width. The arc overlap is necessary to create smooth dose transition between the
sub-PTVs. With the collimator at 0° there was ample overlap between the beams but
this geometry failed to provide "tangential" beamlets, which are critical in getting
dose to structures such as the ribs without overdosing the underlying OARs, such as
the lungs.

An analysis of this "rib problem" is shown below in figure 1. Increasing

the collimator to 45° provided sufficient overlap region to give smooth dose
distribution between the sub-PTVs, and fairly good but not excellent PTV coverage
due to some parts of the PTV missing that “tangential” beam. Finally, rotating the
collimator to 90° provided excellent lateral coverage but the fields as designed were
not long enough to overlap with each other as shown in figure 2a. To remedy the
overlap regions, a carriage shift between the co-isocentric arcs was implemented to
allow the entire PTV coverage. A schematic of this beam setup is shown in figure 2c.
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1a

1b

Figure 1. A schematic of the "rib problem". Both images show a RapidArc beam at
two different gantry angles. Although zero collimator rotation (1a) appears to have
good coverage, it is too narrow to allow any "tangential" beamlets to the ribs. Any
dose to the ribs must also pass through the lungs. Image (1b) is an example of 90°
collimator angle, showing how the much wider beam provides excellent access to
tangential beamlets through the ribs, which avoid the lungs.
(a)

(b)

(c)

Figure 2. Eight arcs shown in three configurations. a) with a collimator rotation of
90°, showing lack of overlap with adjacent fields, b) with a collimator rotation of 45°,
showing both good coverage and good overlap. (Note that the white areas of the
body are fully covered as the arcs rotate around the body.) c) with a 90° collimator,
but with the beams moved asymmetrically (fields are shown offset left and right for
clarity).
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3.3

Results
Both Eclipse and VoLO plans were normalized to deliver 1200 cGy to 95% of

the PTV, and evaluated for mean, maximum and D10 PTV doses as well as mean
dose and D10 to OARs.
3.3.1 PTV Analysis
The TomoTherapy plan resulted in superior coverage of the PTV, with a very
steep DVH curve, increasing only about 100 cGy from the D95 level to the D10 level
(figure 3). The Eclipse plan compared favorably with the Tomo plan, but was slightly
"hotter", increasing about 156 cGy from D95 to D10. The max doses (table 5) differ
by 76cGy between the two plans, with 1465 and 1541 cGy for TomoTherapy and
Eclipse, respectively.

Figure 3. Doses to PTV, Lung and Small Bowel.
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D95

Mean Dose

TomoTherapy
1200
1268
Eclipse
1200
1284
Table 5. Dose to PTV, in cGy.

D10

Max Dose

1297
1356

1465
1541

3.3.2 OAR Sparing
The results of the critical OAR sparing for the two planning systems are
presented in figures 3 to 5. The mean dose and maximum doses of all OARs
considered are shown in table 6. The mean dose and D10 to every OAR was
between 3% to 52% lower for the TomoTherapy plan, with the exception of the small
bowel, where the Eclipse plan was slightly better.

Figure 4. Heart and Brain DVHs.
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Figure 5. Kidney and Liver DHVs.
Due to its important role in post-BMT toxicity, the primary OARs considered in
this study were the lungs. The right and left lungs were considered as a single
structure for dose analysis. The mean dose to total lung in the TomoTherapy plan
was 677 cGy, compared to 864 cGy for Eclipse. It is worth noting that both the
TomoTherapy and Eclipse plans are below the ~9.4 Gy mean lung dose threshold
discussed in the Volpe et al.40 paper.
Lung

Brain

Heart

Liver

Small Bowel

Kidneys

Mean

D10

Mean

D10

Mean

D10

Mean

D10

Mean

D10

Mean

D10

Tomo

677

1045

723

1146

294

446

496

643

558

690

345

492

Eclipse

864

1185

1188

1311

489

637

762

973

548

713

720

877

Difference

22%

12%

39%

13%

40%

30%

35%

34%

-2%

3%

52%

44%

Table 6. OAR doses in cGy. Difference shown as (Eclipse-Tomo)/Eclipse.
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3.3.3 Treatment Planning Time
Although the time required to create a TMI plan would vary considerably
based on both the skill of the planner and the speed of the computer used, an
attempt was made in this study to track time spent on various tasks. These results
are given as information for those planning to implement or study TMI in order to
give a broad idea of times that may be required.
This process of optimization and dose calculation is from the conclusion of
beam placement, prescription selection and selection of all optimization parameters
to the conclusion of all dose calculation steps. Only software optimization and dose
calculations times were therefore evaluated. Other tasks that are user dependent
are not included in the results. The times are reported for the final plans created by
each system.
Final computation time for Tomotherapy which consisted of optimization time
and final dose calculation time was 0.9 hours. The optimization time took the
majority of the computational time. The optimizer was run until there was no further
visual improvement of the DVH with additional iterations. The objective functions
were chosen by trial and error to achieve a plan with lowest PTV hot spots and
lowest OAR doses.
The Eclipse final plan consisted of four separate plans. Each sub-plan was
optimized several times to minimize hot-spots in the overlap regions. The final
computation times, including optimization and dose calculation for the four plans was
3.8 hours.
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3.3.4 Beam-On Time
In a simplified case, beam-on time would only be dependent on machine
output (dose rate) and fraction size (dose). Beam-on time increases with dose and it
is inversely proportional to the dose rate. In the Varian system the dose rate is
variable and during beam delivery the dose rate is adjusted based on MLC and
gantry position (in RapidArc mode). The more modulated (complex) the plan the
lower the dose rate due to maximum MLC leaves speed limitations. In our study the
dose rate varied between 200-300 MU/min, effectively delivering each arc in
approximately 76 seconds for the total of 608 seconds.

The dose rate of

Tomotherapy is fixed at approximately 860 MU/min. Beam-on time in Tomotherapy
is dependent on gantry speed, field size and the pitch. Despite higher dose rate,
TomoTherapy’s maximum field size is limited to 5cm in the longitudinal direction as
opposed to up to 40cm for Varian, and due to the helical delivery mode with pitch of
0.287 the beam-on time was much longer at 1148 seconds. Older Tomotherapy
systems were reported52 to have problems with dose rate constancy which would
affect final dose delivered to the patient. Our unit is equipped with a Dose Control
Servo (DCS) system which keeps the output rate steady at 860 MU/min.
3.4

Discussion
The TomoTherapy TPS was able to achieve the best PTV coverage and

superior sparing of most OARs. The helical nature of TomoTherapy delivery along
with 40cm lateral field size allows the beam to enter from any angle and cover the
entire PTV in the lateral direction. With pitch of 0.287, every voxel of the PTV “sees”
the entry beam over 3 times. In a conventional C-arm gantry linac, the same voxel
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will only “see” the entry beam once per arc. Tomo plans therefore result in more
homogeneous dose distribution in the PTV and lower doses to the OARs due larger
solution space available to the optimizer.
The differences in the plan quality are presented here for one case only and
are meant to show general differences between the modalities and their respective
treatment planning systems.

Individual results of the OARs will be strongly

dependent on optimization parameters chosen, their weights and priorities.
Individual planning skillset as well as clinical practice will also influence final
planning results.

Even if it was possible to set the same optimization objectives

between the two modalities, the plan differences would still exist due to different
calculation algorithms. Eclipse TPS uses analytical anisotropic algorithm (AAA) and
Tomotherapy utilizes collapsed cone convolution superposition (CCCS) algorithm for
dose calculations. The AAA is pencil beam like superposition algorithm that uses
only analytical functions for calculations. It makes assumptions that the dose at any
given point is the sum of contributions of a depth dependent and a lateral part. In
heterogeneous tissue the beamlet attenuation and lateral energy kernel are scaled
based on “equivalent path”. The CCCS is volume based algorithm where primary
energy is convolved with polyenergetic kernel that describes the energy spread of
secondary particles and accounts for the lateral transport of energy.

In

heterogeneous media, the kernels are scaled using mass stopping power ratio and
mass attenuation coefficient ratio. Both algorithms have been extensively studied
and compared to the “gold standard” of Monte Carlo (MC) algorithm. Generally, the
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CCCS algorithm show less deviation from MC as compared to AAA especially in
heterogeneous tissue.110
Planning a TMI case in the TomoTherapy software followed routine planning
processes regardless of the length of the target volume. However, the planning
process in Eclipse required matching multiple arcs using multiple isocenters and was
a cumbersome process. The sheer size of the PTV required several arcs to achieve
an acceptable plan but the number of total arc degrees between all arcs in a plan is
limited to 1500 degrees. The necessity of splitting the PTV in to smaller sub-PTVs
was laborious and complicated as some of the organs overlapped two sub-PTVs,
making the choice of optimization parameters for these structures difficult.

The

complexity of multiple isocenter plans in Eclipse also affects the treatment delivery.
Although the beam-on time for Eclipse plan for Varian IX linac was just over half of
that of TomoTherapy, the overall treatment time difference will be significantly
smaller since for every isocenter, the therapists have to enter the room and
reposition the patient.
It would be very difficult to accurately estimate the total time required to plan a
TMI case on each planning system. Total time is dependent on the experience of
the planner and the number of trials to achieve acceptable plan. Tracking total time
therefore would be user dependent and very subjective. However, the tasks of
optimization and dose calculation times can be objectively evaluated. The much
longer time necessary for Eclipse to optimize and calculate the plans was partly due
to the different optimization and dose calculation algorithms as well as the need to
repeat the process for each sub-PTV. TomoTherapy takes advantage of the parallel
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nature of the GPU system as described by Lu at al.32 which can process data up to
20 times faster than comparable CPU based systems.42 Dose delivery validation for
TMI plans has been previously reported by Hui et al.31 and Corvo et al.43 therefore
validation measurements have not been performed in this study.
3.5

Conclusions
The results of this study have demonstrated that the new TomoTherapy VoLO

planning station was able to create better TMI treatment plans in terms of PTV
coverage and OAR sparing.

In addition, the simplicity of planning process as

compared to multiple plans on Eclipse makes TomoTherapy the better choice for
planning TMI treatments. Another advantage of the VoLO system used in this study
was the ability to optimize and calculate the TMI plan about four times faster than
Eclipse.

With advancements in the software and continuous improvements in

computational speed, the planning times may not be a factor in the future.
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CHAPTER 4 “TOTAL MARROW IRRADIATION: A COMPREHENSIVE
APPROACH TO TREATMENT PLANNING FOR HELICAL
TOMOTHERAPY”
4.1

Introduction
Total body irradiation (TBI) plays an important role as an immunosuppression

agent in patients undergoing bone marrow transplantation (BMT).17 Traditionally the
dose is delivered using standard radiotherapy equipment such as linear accelerator
or Co-60 teletherapy machines. Due to the radiation field size limitations of these
devices in treating the entire bone marrow, the patients are often treated at extended
distances taking advantage of the divergent nature of the beam. Patients are
positioned to be treated either bilaterally or anterior-posteriorly.37-39 Two opposed
beams deliver the prescription dose specified at the mid-depth with a goal of dose
uniformity of ±10%. If the patient thickness varies significantly, additional blocks are
used to keep the dose uniformity within 10%. If the beam is delivered uniformly to
the entire body, as is conventionally performed, every organ at risk receives
approximately the prescription dose. With higher doses it is common to use lung
blocks to reduce the dose to the lungs and decrease the risk of pneumonitis.
Radiation pneumonitis is the most critical morbidity, and a mean dose of 9.4 Gy to
the lungs results in a significant increase in post-BMT mortality.40 Although higher
doses reduce post-transplant relapse, the excessive toxicity in organs at risk
reduces the overall survival with the traditional two field delivery methods.21,22
With the use of intensity modulated radiation therapy (IMRT) it is now
possible to deliver the prescription dose to the bone marrow only, while sparing
critical organs, a treatment called Total Marrow Irradiation (TMI). Feasibility studies
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have

shown

that

conventional

C-arm

linear

accelerators23,26,27,44

and

Tomotherapy28,30,31,42,45 can be used to deliver TMI treatments and provide dose
reductions of 29%-70% to critical organs relative to conventional TBI treatments.
One of the major limitations of TMI is the long treatment time necessary to deliver
these modulated fields. Wielkie et al.23 reported TMI treatment times of nearly 60
minutes. The majority of this time was spent on patient and treatment field setup to
deliver the entire plan which consisted of 3 sub-plans. The combined beam-on time
for the three sub-plans was only 14 min. Tomotherapy beam-on times for TMI have
been reported28,30,31,42,45,46 with a vast range of 15-50 minutes depending on
optimization parameters used.
In this study we used the new Graphics Processing Unit (GPU)-based
treatment planning system VoLO (Accuray, Sunnyvale, CA) to create TMI treatment
plans for helical delivery on Tomotherapy. The plans were created with a range of
clinically acceptable machine optimization parameters. The goal of this study was to
develop a TMI planning guide and aid planners with selection of machine
optimization parameters to improve the planning results based on desired
objectives.

A plan quality index (Q) was developed for quantitative analysis of

relative plan quality which included mean and maximum doses and beam on time.
4.2

Methods and Materials
In this study we utilized an anthropomorphic Rando phantom (The Phantom

Laboratory, Salem, NY) to create TMI treatment plans using the VoLO treatment
planning system. The Rando phantom has a human skeleton embedded and is built
of a material radiologically similar to soft tissue. It extends from head to mid-femur
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and does not have extremities.

The phantom was placed in an immobilization

device and simulated for treatment using a large bore Somatom Sensation CT
scanner (Siemens, Malvern, PA) to acquire a full phantom CT image set with 5mm
slice thickness. A planning target volume (PTV) was created by delineating the bony
skeleton with the exception of the mandible. An additional margin of 5 mm was
added to the ribs and femurs to account for motion. A typical TMI PTV extends from
the most superior part of the skull to about mid-femur. It was assumed that since
lower extremities don’t have critical OARs they would be treated conventionally with
2 sets of abutting AP/PA fields. Evaluated organs at risk (OAR) consisted of lungs,
brain, heart, liver, small bowel and kidneys. Since Rando does not have any of
these organs other than lungs, the remaining OAR contours were created by a
physician to closely approximate their typical size and location.
Optimization objectives were chosen based on previous clinical TMI cases
with a goal of reducing the mean dose of OARs to 50% of the prescription dose of
1200 cGy while delivering the prescription dose to 95% of the PTV.

The user

selectable machine parameters are the field width, pitch and modulation factor. The
field width is defined in the superior-inferior (S-I) direction and, since the PTV is
extremely large in the S-I direction, only 2.5 and 5cm field widths were evaluated.
The pitch is defined as the fraction of the field width that the couch moves per gantry
rotation.

Pitch values in this study were chosen using the following equation:

p=0.86(1/n) where the 0.86 factor is empirical -- caused by beam junctioning --and
‘n” is an integer. This pitch equation was originally derived by Kissick et al.34 to
minimize the ripple effect as a result of helical beam junctioning. The pitch values
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considered here were obtained for n=1, 2, and 3 corresponding 0.86, 0.43, and
0.287, respectively. The third parameter evaluated was the modulation factor (MF),
which is defined as the ratio of the maximum leaf open time to the average leaf open
time. Tomotherapy has binary leaves which are either open or closed and the leaf
openings are defined through 51 “projections” (approximately 7 degrees) of the
gantry rotation and beam modulation is achieved by varying the time that each leaf
is open during a projection.

Shorter average leaf open times mean greater

modulation and result in a larger MF. The modulation factor is set by the planner as
a target value for the optimizer (usually 2.0 for clinical cases) and depending on
target and OAR constraints, the actual value returned by the optimizer for the plan is
within ~20% of the set value. Modulation factors used in this study ranged from 1.25
to 3.0 at 0.25 intervals.
Using one image set and structure set, each TMI plan was optimized for 100
iterations after which the final dose was calculated. The 100 iteration cutoff was
chosen based on clinical experience that has demonstrated negligible improvements
to dose-volume parameters when allowing further iterations during optimization.
Keeping the PTV and OAR objectives the same, the plans were re-optimized with
varying field size, MF, and pitch. A summary of all parameter value sets evaluated in
this study is presented in table 7.
Field Width (FW)

2.5 and 5.0 cm

Pitch
0.287, 0.43 and 0.86
Modulation Factor
1.25 - 3.00 @ 0.25
(MF)
intervals
Table 7. Machine optimization parameters.
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Mean and maximum doses for each structure and delivery time for the
treatment were compared between plans. In addition, plan quality index (Q) was
developed to calculate a relative quality value for each plan. The basic form of
equation for Q is shown in Eq. 1:
∑ ln
where, = PTV and OARs,

= actual dose achieved,

(1)
= Reference dose, and

= weight as presented in table 8.
parameter
PTV
Maximum
1320 cGy
Lung
Mean
940 cGy
Brain
Maximum
1200 cGy
Heart
Mean
600 cGy
Liver
Mean
600 cGy
Small Bowel
Mean
600 cGy
Kidneys
Mean
600 cGy
Table 8. PTV and OARs constraints.

2
3
1
1
1
1
1

Mean reference doses were chosen as half of the prescription dose for all
OARs other than lung. The dose tolerance limits for all OARs studied here except for
lung are well above the prescription dose of 1200 cGy. The weights for these OARs
were therefore set at 1 to have the same relative impact on the quality index.
Radiation pneumonitis is the most critical morbidity60 therefore the reference mean
lung dose was set at 940 cGy and the relative weight was chosen as 3. This higher
weight for lung mean dose was chosen to have higher impact on the quality index
and penalize treatment plans that resulted in mean lung dose approaching the limit
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of 940 cGy. Maximum PTV reference dose was set at 110% of the prescription or
1320 cGy, based on clinically acceptable dose heterogeneity.
4.3

Results

4.3.1 Field Width.
Plans created with 2.5cm field width had lower PTV mean and maximum
doses than plans with 5.0cm field width with the same pitch and MF while
maintaining the prescription coverage of 1200 cGy to 95% of the PTV. Figures 6-7
show differences in mean and maximum doses between both field widths for two
combinations of pitch and MF. On average the mean and maximum PTV doses were
lower for the 2.5cm field width by 0.8% and 4.3%, respectively. Similar results were
observed for all the OARs. On average the mean and maximum OAR doses were
lower for the 2.5cm field width by 4.1% and 4.3%, respectively.

Figure 6. Relative dose difference between FW 2.5 and 5.0cm. Pitch 0.43 & 1.5 MF
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Figure 7. Relative dose difference between FW 2.5 and 5.0cm. Pitch 0.287 &2.5 MF.
4.3.2 Pitch.
In general, the mean and maximum PTV and OAR doses decrease with
decreasing pitch with all other parameters constant. For each reduction in pitch the
average OAR mean dose was lower by 3.5% and the average maximum dose was
lower by 2.0%. The PTV resulted in average mean and maximum dose reductions of
0.8% and 0.7%, respectively, with lower pitch values. Figures 8-9 show two
representative examples.
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Figure 8. Relative dose difference between pitch 0.287, 0.43 & 0.86. FW 2.5, 2.5MF.

Figure 9. Relative dose difference between pitch 0.287. 0.43 & 0.86. FW 5.0, 1.5MF.
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4.3.3 Modulation Factor.
Overall, higher modulation factor resulted in lower mean and maximum doses
to the PTV and OARs. The effect of changes in MF on plan quality was larger at
lower MF values. The relationship between PTV and OAR doses and modulation
factor is illustrated by figures 10 and 11. For plans with a pitch of 0.86, each change
in modulation factor of 0.25 changes the beam on time by an average of 10%. The
same effect is observed in plans with a pitch of 0.43 and MF >2.0.

Figure 10. Relative dose difference as a function of MF. FW 2.5, Pitch 0.287.
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Figure 11. Relative dose difference as a function of MF. FW 5.0, Pitch 0.287.
4.3.4 Beam delivery time.
With one exception, the beam on time increases with increasing MF and/or
decreasing pitch for plans with either field size. At the same time, the plan improves
with increasing MF and/or decreasing pitch. Figure 12 shows combined effects of
the three parameters on beam on time. The beam on time for 2.5cm FW was 85%99% longer than that for 5.0cm FW for the same pitch and MF.
4.3.5 Plan quality index Q.
Relative plan quality results combining all three optimization parameters is
presented in figure 13.

Plans with smaller pitch values and smaller field size

resulted in higher plan quality index.

Plan quality also increases with MF and

approaches a plateau at the highest MF studied.
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Figure 12. Beam on time as a function of MF.

Figure 13. Plan quality summary.
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4.4

Discussion.
In this investigation we demonstrate the effects of user selectable parameters

(field width, pitch and MF) on relative plan quality keeping all other optimization
parameters invariant. As expected, smaller field width provides better control of
dose distribution in the cranial-caudal direction resulting in lower OAR doses and
better PTV coverage when these volumes are in close proximity. With decreasing
pitch the solution space for the optimizer is increased, resulting in better quality
plans. In other words, each voxel is covered by a greater number of rotations in the
helix when using a smaller pitch, giving the optimizer more choices to find the
optimal beam fluence. Increasing the modulation factor will also improve plan quality
by allowing a wider range of leaf opening times between projections, which in turn
increases the dynamic range of the beam fluence.
By definition, the modulation factor is a ratio and therefore increasing a low
MF by 0.25 will have a larger effect on the dose distribution than increasing a high
MF by the same amount. The change in beam on time with changing MF is fairly
linear for plans with 0.86 pitch. There is no effect on beam on time when changing
MF for plans with a pitch of 0.287 and plans with pitch of 0.43 and MF below 2.0.
These effects are observed for both field sizes. With low pitch and/or modulation
factor the gantry has to rotate faster to deliver the prescribed dose because the
radiation output is not variable. With pitch of 0.287 the gantry is approaching the
maximum rotational speed therefore having no effect on the beam-on time with
changing MF. The same effect is noted for plans with low MF (<2.0) and pitch of
0.43.
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Accounting for the ripple effect described by Kissick et al.34 there are only
three clinically usable values for TMI planning: 0.287, 0.43 and 0.86. Values larger
than 1.0 would not provide the necessary beam overlap and plan quality would be
degraded. The next smaller value would produce plans with excessive beam on
time. One could experiment with other values not suggested here and ignore the
ripple effect since it may not be clinically significant for the relatively large acceptable
tolerance in dose heterogeneity for TMI (±10%). Both the MF and pitch have an
incremental effect on plan quality as described in the results section.

There is

significant variation in beam on time as a function of modulation factor for plans with
pitch of 0.86. This effect is also observed in plans with pitch of 0.43 and MF above
2.0. The pitch selection has the largest effect on beam on time, on the order of
40%-50%, for plans with the lowest tested MF of 1.25. The most significant effect on
beam on time comes from the selection of the field width. Plans with field size of
2.5cm had marginally (up to 4.3%) lower doses to PTV and OARs as compared to
plans with 5cm field width at the expense of significant increases in beam on time.
The increase in beam on time for the smaller field size plans varied between 85%
and 99%.
The figures and data reported here represent planning results of just one
image set and one structure set and are meant to be used for relative comparison
between plans with varying parameters. The absolute OAR and PTV doses should
not be used for absolute comparison or considered optimal. The PTV coverage and
level of OAR sparing will vary from clinic to clinic based on their clinical objectives.
The beam on time reported in figure 12 is also only representative for our particular
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case. With all parameters invariant, the beam on time will depend on the extent of
the PTV in the cranial-caudal direction due to the nature of helical delivery.
4.5

Conclusion
All the optimization parameters have an effect on final plan quality and beam

on time. In general as plan quality improves the beam on time increases. Overall,
plans with 2.5cm field width will result in better quality but it is possible to achieve
comparable if not better plans with 5.0cm field width by decreasing pitch and/or
increasing MF. Adjusting the parameters for better plan quality will reach a point of
diminishing returns. Very long beam on times will compromise patient comfort, may
cause the machine to overheat and could reduce dose delivery efficiency do to
highly modulated fluence.
While it would be difficult to recommend specific optimization parameters in
general for TMI using Tomotherapy, the results presented here provide a
compendium of clinically relevant results that can help the planner understand and
anticipate the relative effects of changes in particular parameters. In some cases,
for example pediatric patients under anesthesia, faster treatment may be a priority.
In cases for which dose escalation is necessary, treatment time might be considered
less relevant than OAR sparing. The results presented here not only give results
representative of what one might achieve for real clinical cases, but also insight into
how to improve the resulting plan characteristics in particular situations without the
need for exhaustive planning comparisons varying all of the parameters studied
here.
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CHAPTER 5 “SINGLE FRACTION RADIOSURGERY/STEREOTACTIC BODY
RADIATION THERAPY (SBRT) FOR SPINE METASTASIS: A DOSIMETRIC
COMPARISON OF MULTIPLE DELIVERY PLATFORMS”.
5.1

Introduction.
Spinal metastases are a common oncologic occurrence that can have a major

impact on the cancer patient’s quality of life and functional status. It is well known
that radiation therapy is an excellent palliative treatment for spine metastases.
Currently accepted radiation techniques include a variety of fractionated regimens as
well as single fraction treatment, which has historically been delivered at a dose of
8Gy. Multiple studies have shown these techniques to result in a pain response of
approximately 60%.47-48 More recent data supports the use of stereotactic body
radiation therapy (SBRT) or radiosurgery for spinal metastases with fewer fractions
delivered and greater, more durable responses. Gerszten et al. reported that 86% of
patients experienced long-term pain improvement and excellent local control utilizing
SBRT.49 In current practice, an increasing percentage of patients with spine
metastases can experience long-term survival. As systemic therapy continues to
improve, it becomes even more important to produce durable pain palliation and
local control.50
SBRT is commonly defined as a treatment that couples a high degree of
anatomic targeting accuracy and reproducibility with very high doses of extremely
precise, externally generated, ionizing radiation delivered in 5 or fewer fractions to
an extracranial target. Treatment consisting of one fraction only is referred to as
radiosurgery. The use of radiosurgery/SBRT has increased significantly over the
last several years. A recent survey of radiation oncologists practicing in the United

53

States reported that 63.9% use SBRT for selected patients, the most common
treatment locations including lung, spine, and liver.51 As utilization of this technique
increases, so have the number of platforms designed to deliver such treatment. At
our own institution, we have multiple treatment planning and delivery systems used
for highly conformal SBRT treatments, but no set guidelines for choosing between
them. In order to precisely deliver the intended dose and spare adjacent spinal cord,
these systems require advanced planning and delivery capabilities. The new GPU
based TPS from Accuray has been shown to be accurate and very fast in planning
TMI cases and its capabilities will be tested for small and highly conformal targets
such as in SRS and SBRT, and compared with other modalities. The systems’ new
dynamic jaws should further influence plan quality and treatment time.
Previous reports on modality selection for SRS/SBRT have been published
for intracranial sites and were either limited to two platforms52 or compared based on
technical specifications.53 Within this study, we attempt to determine whether there
are significant differences in planning and delivery capabilities across these
platforms within the context of the current RTOG 0631 radiosurgery/SBRT spine
trial.

Therefore we designed sample spine metastasis cases within a phantom

model and generated radiosurgery treatment plans for five different planning and
delivery systems. We hypothesized that, while each modality would be able to meet
the constraints of RTOG 0631, there would be differences in dose to critical normal
tissue, treatment time, and dose fall off that may assist in the choice of delivery
system based on characteristics of the individual case and target shape/volume.
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5.2

Methods and Materials
Radiotherapy treatment simulation was performed on an anthropomorphic

thorax/abdomen phantom (Integrated Medical Technologies, Troy, NY) using a 40slice CT scanner with 1.5mm slice thickness. Sample spine radiosurgery plans were
created using idealized target volumes created on the phantom. Target volumes
were designed using the Eclipse (Varian Medical Systems, Palo Alto, CA) treatment
planning system in accordance with parameters in the International Spine
Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in
Spinal Stereotactic Radiosurgery54 and the recommendations of RTOG 0631. Four
distinct target volumes representing typical case presentations of spine metastases
were contoured in both the thoracic and lumbar spine of our anthropomorphic
phantom. Target volume "A" included a single vertebral body, target volume "B"
included all elements of a single vertebral level completely encircling the spinal cord,
target volume "C" included only the spinous process of a single vertebral level, and
target volume "D" included two consecutive vertebral bodies (figure 14). The spinal
cord was contoured as a structure approximately 7mm in diameter, contained
centrally within the bony limits of the spinal canal. The contoured cord was designed
to reflect the average cord size of our previous ten radiosurgery spine patients who
were planned using fusion of MRI or CT myelogram as well as measurements
reported in the literature.55 To ensure comparability, each contour and image set
was communicated unaltered from Eclipse to each of the other treatment planning
systems through DICOM-RT.
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Figure 14. Axial representations of target volumes (Red) and spinal cord (Green)
along with sagittal image of target “D” to illustrate its extent across two vertebral
levels.
Dose objectives and constraints were designed to meet those required for
RTOG 0631 and the target was prescribed 16Gy in a single fraction.

Briefly,

planning requirements included the following: at least 90% of the target volume
receives the prescribed radiosurgery dose; hotspots outside the target were limited
to 105% within 1cm of the target volume and 110% anywhere outside the target.
Spinal cord constraints included 10Gy to 10% of the partial spinal cord defined as 56mm above and below the target, the total volume of spinal cord receiving 10Gy was
restricted to below 0.35cc, and the absolute maximum dose to the spinal cord was
restricted to 14Gy to a volume of no more than 0.03cc. Additional OAR constraints
included cauda equina volume of <0.03cc receiving 16Gy, and <5cc receiving 14Gy.
The total lung was limited to a volume of less than 1000 cc receiving 7.4 Gy. A point
dose of 110% of the prescribed dose was allowed outside the target volume as long
as it was less than 0.03cc, which is an acceptable variation per the protocol.
With these objectives, single fraction radiosurgery plans were designed for
each target to be delivered with CyberKnife (CK) with Iris collimator (Accuray,
Sunnyvale, CA), Tomotherapy with TomoEDGE™ dynamic jaw (Tomo) (Accuray
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Sunnyvale, CA), Vero (BrainLAB, Feldkirchen, Germany and Mitsubishi Heavy
Industries, Tokyo, Japan), and Varian TrueBeam (Varian Medical Systems, Palo
Alto, CA), the latter utilizing RapidArc (RA) in standard and flattening filter free (FFF)
modes. The plans for each system were designed by experienced dosimetrists and
physicists responsible for planning clinical cases on these systems.

Within the

constraints listed, the planner was asked to design the best possible plan with
priority on the spinal cord constraints. The planners were blinded to the planning
techniques and results of other modalities so as to not influence their results. Each
institution chose planning (dose calculation algorithm, grid size, etc.) and machine
parameters (number of fields, pitch, gantry angles, etc.) according to their clinical
practice.
For the Varian TrueBeam RapidArc with and without flattening filter plans, the
Eclipse (v. 10.0.39) treatment planning system was used to create two complete
arcs. Dose calculation was performed using the Analytical Anisotropic Algorithm
(AAA) using a 2.5mm dose grid. The iPlan (v. 4.1.2) treatment planning system was
used to create the Vero treatment plans, utilizing a 2mm dose grid. Thirteen
coplanar IMRT beams were uniformly distributed through 360 degrees, and the
Monte Carlo dose algorithm was used. For Cyberknife, the MultiPlan (V 5.1)
treatment planning system was used with the Monte Carlo Algorithm with high
resolution and a 1.0mm x 1.0mm x 1.5mm grid for dose calculation. For the
TomoEdge plans, the Tomotherapy VoLO (v. 5.0.0.0) treatment planning system
was used with a 2mm grid size used for dose calculations.
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We analyzed these plans with priority on the dose to 10% of the partial spinal
cord and dose to 0.03 cc of the spinal cord. The Paddick dose gradient index (PGI),
defined as the ratio of the volume encompassed by half the prescription dose to the
volume encompassed by the prescription dose, was used as a measure of the
steepness of the dose gradient around the target.56 Once we confirmed that each
system was able to meet all of the target goals of the protocol, we compared these 2
cord metrics along with their ability to limit the dose to other surrounding tissues
using the PGI.
5.3

Results.
A total of 40 plans were generated for the cases listed above (eight for each

platform – one for each lumbar and thoracic target).

Each system was able to

generate plans delivering the prescription dose to 90% of the target volume while
meeting all the constraints of RTOG 0631. RA and Tomo achieved the most
homogeneous dose distribution within the target. D95 was on average 99.5% and
99.2% of the prescription dose for RA and Tomo, respectively. D95 results for CK
and Vero were on average 93.0% and 95.2%, respectively. Target volume C, which
was the smallest of the targets, showed the most variability between modalities. For
example, the maximum cord dose to 0.03cc was 13.1Gy for RA-FFF versus only
7.7Gy for Vero. Both Vero and CK had lower cord doses and sharper dose falloff
than the other modalities for target C. On average, as displayed in figures 15-22, CK
was able to achieve the lowest cord doses overall and also generated the sharpest
dose falloff as indicated by the Paddick gradient index.
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Figure 15. Lumbar Target A.

Figure 16. Lumbar Target B.
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Figure 17. Lumbar Target C.

Figure 18. Lumbar Target D.
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Figure 19. Thorax Target A.

Figure 20. Thorax Target B.
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Figure 21. Thorax Target C.

Figure 22. Thorax Target D.
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Figure 23 provides a visual representation of the dose distribution created by
each modality for the two most complicated cases, B and C. Treatment times varied
widely depending on the modality utilized. On average, treatment can be delivered
faster with RA-FFF and Tomo, compared to RA, Vero and CK (table 9). It should be
noted that we are reporting treatment times for Tomotherapy Edge with dynamic
jaws. Treatment times for Tomotherapy with static jaws were 3 to 5 times longer
than with Tomo Edge depending on the target.

Figure 23. Isodose distribution for Targets B and C (Red) and their relationship with
the spinal cord (Purple). Isodose line are as follows: 16.8 Gy – Orange; 16.0 Gy –
Black; 14.4 Gy – Green; 12.0 Gy – Light Blue; 8.0 Gy – Dark Blue.
Modality

Average (min)

Range (min)

RA

9.5

7.2-11.2

RA-FFF

4.4

3.5-4.9

Tomo

6.0

5.0-6.8

CK

58.1

32.0-85.0

Vero

19.1

15.0-24.5

Table 9. Average beam on times across all targets for each modality.
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5.4

Discussion
With the rapid innovation that is characteristic of the field of radiation

oncology, it is important to ensure that adoption of new technology is done with a
priority on safety. The delivery of high doses per fraction with radiosurgery/SBRT
decreases our margin for error compared with traditional fractionated radiation.
Especially in spine radiosurgery/SBRT cases with tumors adjacent to the spinal
cord, it is critically important to minimize dose to normal structures while at the same
time maintaining the ability to deliver adequate dose to the target. In our study we
have shown the dosimetric results of a representative set of cases planned with
multiple delivery platforms. These do not by any means encompass the wide variety
of cases seen in clinical practice, nor do the 40 plans generated in our study
represent the capabilities of other planning teams. Additionally, we recognize that
small inaccuracies in patient setup and variability in actual treatment delivery can
have serious and significant consequences that could far exceed the differences
between modalities that are presented here. Indeed, evaluation of the relative ability
of each of these systems to accurately deliver these treatment plans is critical in
determining whether there is any real advantage to one over another.
In an associated quality assurance analysis study,
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both ion chamber and

film were used to measure delivered dose for all plans on each modality presented
here. The results of these measurements were exceptional, specifically that all ion
chamber measurements were within 3.3% of the dose predicted by the respective
treatment planning system and all modalities yielded film gamma pass rates better
than 96% at 2%/2mm. Finally, while we identified situations in which some systems
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provide a dosimetric advantage in treatment plan characteristics for a particular
SBRT spine treatment, it is not clear if these differences would translate into a
clinical advantage.
We believe that the ability of CK to achieve overall superior dosimetric results
comes from use of the smallest aperture and a greater number of possible beam
orientations. The CK was the only modality in this study that used non-coplanar
beams. The difference between the Vero and TrueBeam results could be attributed
to the number of beams since 13 coplanar beams were used for the Vero plans and
only 2 arcs were used for the TrueBeam plans. Both machines have an MLC leaf
width of 5mm.

Also, Burghelea et al.52 showed that smaller aperture and non-

coplanar beams produce plans with better conformity and dose gradient for small
targets. Both TrueBeam and Vero could benefit from using non-coplanar beams. In
addition, the use of the high definition MLC (HDMLC), which has 2.5mm leaf widths,
could be expected to further improve dosimetric results for the TrueBeam plans.
The main objective of this study was to meet or exceed the dose constrains of
RTOG 0631 protocol. Each institution was able to choose optimization and machine
parameters according to their clinical practice. Although, all institution met all of the
constraints of the protocol, there were differences in dose gradient outside the
target. These differences can be attributed to different planning techniques. Some
institutions adhere to common standards when it comes to hot spots within the target
and limit them to 110% of the prescription.

This protocol does not have any

requirements for dose heterogeneity within the target.

Allowing higher hotspots

within the target, as it’s commonly done in linac based or Gamma Knife SRS
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treatments, would result in steeper dose gradients outside of the target.

The

difference in the dose gradient between the modalities could have been minimized if
all the institutions followed the same planning techniques. The results presented
here may also be influenced by the difference in dose grid size used by each
platform. Other studies suggest that variation in dose calculation for grid sizes used
in our study could be around 2-3%.58-59
Depending on the goals of treatment, the order of importance of the treatment
plan metrics we reported might vary. For example, in the case of a terminal patient
with significant difficulty lying in the treatment position, the physician might decide
that a short treatment time is more important than a sharp dose gradient or the
potential risk of late neurologic complications.

However, a patient with a better

prognosis might tolerate the treatment well, and in that case lower doses to critical
structures would justify a longer treatment time.
5.5

Conclusion.
While all treatment modalities tested were able to create and very accurately

deliver treatment plans meeting the dose constraints of RTOG 0631, we observed
variations that may impact system selection based on individualized treatment goals.
Certain modalities performed better than the others for specific target shapes and
locations. Vero and CK excelled in treating small volume targets. CK had the
sharpest dose falloff and achieved the lowest overall spinal cord doses at the
expense of longest treatment time. Treatment delivery time was fastest for TB-FFF
and Tomo. These findings could provide guidance in the process of determining
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which of the available modalities would be preferable for the treatment of spine
metastases.
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CHAPTER 6 “ANALYSIS OF DOSE FRACTIONATION REGIMENS FOR TOTAL
BODY IRRADIATION BASED ON INTERSTITIAL PNEUMONITIS RISK
FACTORS.”
6.1

Introduction
Total body irradiation (TBI) is an important component of the conditioning

regimen for patients undergoing bone marrow transplantation (BMT) for a variety of
hematological malignancies.37,38,39,60

While post-transplant relapse rates have

improved with radiation dose escalation, overall survival has not improved due to
excessive treatment related toxicities.21,22 These toxicities, therefore, are the most
important factors in determining the chemotherapy and radiation treatment
regimens. The most common acute toxicities include nausea, vomiting, parotitis,
mucositis and xerostomia.

These are usually preventable with drugs or the

symptoms resolve on their own. One of the most significant complications of TBI
conditioning regimen is interstitial pneumonitis (IP) due to its relatively high
incidence rate and potential for mortality. The incidence of grades 3/4 IP following
BMT which includes a TBI regimen is between 0% and 73% and higher occurrence
has been correlated with total lung dose, fractionation scheme and dose
rate.21,22,40,43,45,61-99 It is also known that alkylating chemotherapy agents have a
synergistic effect on lung toxicity when combined with radiation.100
It is difficult to determine the overall IP risk factors from studies reported by
individual institutions because of variation in conditioning regimens as well as
inconsistent reporting of methods and materials. Until relatively recently, lung dose
statistics in the literature were reported with a large degree of uncertainty due to
relatively simple treatment planning methods and the lack of three dimensional dose
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information.

A literature review by Sampath et al.100 found IP correlation with

Cyclophosphomide (Cy) and lung dose, although the lung dose correlation did not
hold for studies that used multiple fraction per day regimens. In this study we plan to
use a database of over three thousand patients from 42 published manuscripts
presenting data on incidence of IP following TBI for BMT, to quantify a lung dose
response for IP, and to relate it to dose fractionation schemes.
6.2

Methods and Materials
Data for this study was obtained from PubMed search engine and included all

published manuscripts that had IP, BMT, TBI or TMI as nonabbreviated key words.
Only those studies with IP incidence explicitly reported by dose fractionation
regimens were included in the analysis.

Studies were only included if crude

incidence of IP was reported. IP related mortality rates were excluded from this
study. There are many factors that contribute to lung toxicities and it’s hard to
distinguish radiation induced IP from another etiology.

The majority of studies

analyzed here had TBI/TMI and chemotherapy regimen, therefore all IP etiologies
grade 3 and 4 were included in this study. The regimens containing a radiation
component only were treated as zero chemotherapy-dose in the database. The
follow-up time associated with the reported IP incidence rates was not used as factor
in the analysis.
The following variables were obtained from the papers: IP incidence rate, total
radiation dose, number of fractions, lung shielding, lung dose, lung dose per
fractions, number of fractions per day, interfraction interval, lung dose rate,
chemotherapy agent and Cyclophosphamide (Cy) dose. The fractional lung dose
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was calculated by dividing reported lung dose by the number of fractions. If lung
lose was not reported, it was assumed the lung received 100% of the prescription
dose. In some cases, lung dose was estimated from given information about lung
blocks either as percent shielding or half value layer (HVL). The lung dose was then
converted to EQD2 – biologically equivalent dose in 2 Gy fractions using equation 2,
as follows:
2

∗

α/β
α/β

2

(2)

where D is total lung dose, d is fractional lung dose and α/β is a term from the linearquadratic model used to quantify the fractionation sensitivity of tissues. The values
of α/β tested in the analysis ranged from 2Gy to 4Gy.101,102 In order to account for
possible incomplete repair of lung tissue in fractionation schemes that required
multiple fractions per day, the lung dose was further converted to EQD2_repair using
equation 3:

2

_

∗

α/β

1
2

α/β

(3)

Hm in equation 3 is a term used to describe incomplete repair based on time
between fractions and repair half time. Lung dose rate was calculated using this
simple formula:
∗
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If a range of dose rates was provided, then the mean of the range was used in the
analysis.

The most prevalent chemotherapy agent was Cy with nearly 80% of

studies reporting its use. The use and frequency of Cy and other chemotherapy
agents are listed in figure 24. Due to the limited and variable use of the other
chemotherapy agents, only Cy was used as a variable in our analysis.

In the end,

our data set included 42 articles that consisted of 88 patient cohorts and 34 unique
fractionation regimens.

Figures 25 - 26 show the frequency and distribution of

these regimens. The range of all parameters studied here is listed in table10.

Chemotherapy Frequency
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Figure 24. Frequency and type of chemotherapy used.
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Radiation Prescription histogram
40
35

Frequency

30
25
20
15
10
5
0
5

6

7 7.5 8

9 9.99 10 10.2 12 13.213.5 14 14.4 15 15.315.6 16 17 18 20
Prescription (Gy)

Figure 25. Radiation prescription histogram.

Dose per fraction histogram
40
35

Frequency

30
25
20
15
10
5
0

Dose per Fraction (Gy)

Figure 26. Dose per fraction histogram.
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Parameter
Lung EQD2 (Gy)
Lung EQD2_repair (Gy)
Number of fractions
Dose per fraction (Gy)
Fractions per day
Lung dose rate (cGy/min)
Cy dose (mg/kg)
Table 10. Range of parameters used in the analysis.

Range
3.9-26
4.2-26
1-13
1.2-10
1-3
2.2-425
0-200

The first goal of this study was to determine whether the following variables
are statistically significant predictors of IP – (i) lung EQD2, (ii) EQD2_repair, (iii)
dose rate and (iv) Cy dose. Using SPSS statistical software package, version 20.0
(SPSS, Chicago, IL) we performed a multivariate analysis (MVA) of the data by the
step-wise Cox logistic regression. In logistic regression analyses, logarithm of the
odds of the event (incidence of IP) is taken as the response variable and is
regressed on selected predictor variables as defined by the conceptual framework of
the model. The form of the regression model is as follows:
Log (p / (1-p)) = β0 + β1 X1 + β2 X2 + ……………+ βk Xk + ε, where β0 is the intercept
and βi is the slope of logit coefficient corresponding to the predictor variable Xi.
Overall significance of the fitted model is done using Wald’s Chi-square test.
Significance of the logit coefficient or equivalently, odds ratio (OR) estimates are
also calculated using Wald’s Chi square test. Here we test the null hypothesis Ho : βi
= 0 (Odds ratio = 1) against the alternative hypothesis H1: βi ≠ 0 (Odds ratio = ≠ 1).
Predicted probability of incidence of IP is computed using the expression,
Estimated p = eβ0 + β1 X1 + ………+ βk Xk / (1 + eβ0 + β1 X1 + ………+ βk Xk )
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Cox regression analyses were performed using two different models. These
models differ in terms of predictor variables included and also the data set (subset)
used to fit and validate the model. Model I is formed using selected predictor
variables (i) LungEQD2_repair, (ii) dose rate, and (iii) Cy dose. Model II is built
using the predictor variables - (i) LungEQD2, (ii) dose rate, and (iii) Cy dose.
Model 1: Log (p / (1-p)) = β0 + β1 LungEQD2_repair + β2 dose rate + β3 Cy dose + ε1
Model 2: Log (p / (1-p)) = β0 + β1 LungEQD2+ β2 dose rate + β3 Cy dose + ε1
Using the models, dose response curves were generated for different fractionation
schemes.
6.3

RESULTS
Table 11 below reports a summary of Cox logistic regression results for

model I. This model has all the patients irrespective of chemotherapy agents used
and the treatment (radiation or radiation & chemo). Hosmer Lemeshow test which
assesses whether or not the observed event rates match expected event rates
indicate that the overall model fit is good (p = .065). Calculated probability values of
p > 0.05 indicate that model’s observed and predicted events do not differ
significantly. Table 3 reports logit coefficient estimates and the associated odds
ratio for the selected predictor variables Cy dose, Lung EQD2_repair and dose rate.
Cy dose taken as a continuous predictor variable in the model reports significant
association with incidence of IP. Estimated associated OR = 1.006 (95% CI (1.003,
1.009)). This indicates that an increase of one unit in the Cy dose reports an
average increase of 0.6% in the odds of incidence of IP adjusting for the effect of
other predictors. EQD2_repair taken as a continuous predictor variable in the model
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reports significant association with incidence of IP. The estimated associated OR =
1.024 (95% CI (1.002, 1.046)). This indicates that an increase of one unit in the
LungEQD2_repair results in an average increase of 2.4% in the odds of incidence of
IP adjusting for the effect of other predictors. Lung dose rate taken as a continuous
predictor variable in the model reports no significant association with incidence of IP.
B

S.E.

P

OR

95% CI for OR

LungEQD2_repair .024

.011

.029

1.024

1.002

1.046

Dose Rate

.001

.001

.485

1.001

.999

1.003

Cy dose

.006

.002

<.001

1.006

1.003

1.009

Constant

-2.759

.278

.000

.063

Table 11. Cox logistic regression results for model I. OR=odds ratio, S.E. = standard error

Results from model II are very similar to model I and are presented in table 12
below.
B

S.E.

P

OR

95% CI for OR

EQD2

.030

.011

.004

1.031

1.010

1.052

Dose Rate

.001

.001

.437

1.001

.999

1.003

Cy dose

.006

.002

<.001

1.006

1.003

1.010

Constant

-2.865

.279

<.001

.057

Table 12. Cox logistic regression results for model II. OR=odds ratio, S.E. = standard error
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Figures 27-28 respectively show EQD2_repair response functions for all
fractionation regimens and multi-fraction per day regimens along with discrete data
points. The model of predicted lung pneumonitis as a function of mean lung dose
(MLD) obtained from QUANTEC103 is included in the figures for comparative
purposes (orange line).

QUANTEC’s data reports MLD for radiotherapy treatments

with a typical prescription of 60 Gy in 2Gy fractions. Therefore, MLD of 30Gy would
suggest lung receiving 1Gy per fraction. The reported MLD was converted to EQD2
using equation (2) and the resulting predictive model is represented as “QUANTEC
EQD2” in color blue on the graph. The size of the data points (green) represents
relative size of number of patients in the study.

EQD2_repair response function. All fractionation schemes
1.0
0.9
0.8
Fitted resposnse
function
Data points

Probability of IP

0.7
0.6

Quantec
0.5
Quantec EQD2
0.4
0.3
0.2
0.1
0.0
0.0

5.0

10.0

15.0

20.0

25.0

30.0

Lung EQD2 (Gy)

Figure 27. Lung EQD2_repair response function for all fractionation schemes.
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EQD2_repair response function. Multiple fractions per day
1.0
0.9
0.8
Fitted response
function
Data

Probability of IP

0.7
0.6
0.5

QUANTEC IP

0.4

QUANTEC EQD2

0.3
0.2
0.1
0.0
0.0

5.0

10.0

15.0
Lung EQD2 (Gy)

20.0

25.0

Figure 28. Lung EQD2_repair response function for multiple fraction per day
schemes.
6.4

DISCUSSION
The goal of this study was to quantify lung dose response for IP based on

retrospective analysis of published results.

Although both models found EQD2,

EQD2_repair and Cy to be statistically significant predictors of IP incidence, the
magnitude of the effect was very small. The significance of the results may also be
misleading due to the large sample size of our data. Although the models correctly
predict the expected increase of IP with lung dose and Cy the dose response
function doesn’t show a good fit with the discrete data points (figures 27-28). Similar
to QUANTEC’s logistic fit of pneumonitis rates vs MLD data, our curve only shows
gradual increase of IP probability with dose without defined dose levels below which
there is no risk of IP. The y-axis intercept and the slope of the curve also suggest
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poor prediction of actual IP rates. In the case of the logistic fit to multi fraction
regimen data, the curve predicts 11% and 30% chance of IP for zero dose and 50Gy
EQD2, respectively.

This prediction does not correlate well with clinical data

analyzed in this study. We removed the data from single large fraction regimens as
these regimens are not common anymore. Modeling the resulting data was proven
to be even more difficult as the remaining data points were clustered together with
even less points at end of the spectrum of dose or IP rates.
We did not find dose rate to be an independent risk factor for IP.

We

investigated this predictor as a continuous as well as categorical variable and we did
not find correlation between dose rate and IP. We also looked at a number of
subsets of the data including fractionated and single fraction regimens. Some
studies found lung dose rate being a risk factor for IP for single fraction
myeloablative (>8Gy) dose of TBI.64,104 Reports by Peters et al.105,106 state that the
dose rate is of little importance for fractionated (2Gy) treatments since cell death
results predominantly from non-repairable single hit killing. Our analysis agrees with
other studies that have found no effect of dose rate on IP for dose rates up to
8.9cGy/min and doses up to 12Gy.70,107 In contrast, studies by Crruthers et al.86 and
Corvo et al.108 reported correlation of dose rates >7.5cGy/min and >6cGy/min to IP
for fractionated treatments, respectively. There seems to be a threshold lung dose
for fractionated treatments below which dose rate has no effect on IP rates. Girinsky
et al. suggested that the dose rate only relates to IP when total lung dose exceeds 89Gy.

This statement could be supported by the data from City of Hope
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Comprehensive Cancer Center45,98 that show no IP rates for doses of up to 7.9Gy
and instantaneous dose rates of 850 cGy/min.
The majority of the fractionation regimens consisted of 2 or 3 fractions per
day. We have separately analyzed all patients in the database as well as the subset
of these patients receiving multiple fractions per day. Historical TBI treatments of a
single large fraction are not common anymore and we did not analyze them
separately. Sampath et al.100 was able to find a lung dose response for treatments
delivered in a single fraction only but the results may not be applicable to multifraction per day treatments frequently used now.
The large dispersion of the data points as seen in figures 27 and 28 is
potentially the main cause of the dose response prediction failure.

Inconsistent

institutional reporting and limited data for high IP incidence rates or low lung doses
most likely contributed to the failed probability model. Our data did not contain any
studies with patients receiving lung dose below 4.2Gy and the IP rate of 34% or
more was observed in only 57 out of 2384 patients. In addition, most of the lung
dose reported is estimated from surface measurements due to lack of three
dimensional dose information. Some of the data was reported as an average with a
wide range which could have negatively affected the prediction model. Variability of
lung shielding methods and frequency may also contribute to inaccurate reporting of
lung dose.

The use of chemotherapy agents within conditioning regimens was

evaluated for total reported dose only regardless of its concurrent or sequential use
with TBI. Another cause of data spread may be due to differences in reported IP
diagnostic criteria.
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Analysis of the discrete data points shows a lung dose threshold of 7.6Gy
(EQD2_repair, a/b=3Gy, repair half-life = 4hr) that clearly separates studies with no
IP toxicities within multiple fractions per day regimens (figure 28). This dose
threshold was validated using statistical method of recursive partitioning with
essentially the same results.

This dose threshold corresponds to EQD2_repair

doses of 7.2Gy and 7.7Gy for α/β values of 2Gy and 4Gy respectively. The studies
that define that threshold report the use of cyclophosphamide of at least 100mg/kg.
Accounting for the synergistic effect of Cy with radiation and the resulting dose
modifying factor of 1.2 (for 120mg/kg) calculated by Sampath et al.100 the 7.6Gy
threshold observed in our study is equivalent to 9.1Gy (EQD2_repair) for regimens
that do not use Cy or similar alkylating agent.
From our analysis we estimate that a lung EQD2_repair of 7.6Gy delivered in
2Gy fractions twice a day with at least 6 hours separation between the fractions and
Cy of 120 mg/kg should result in negligible probability of IP.

Using the most

prevalent fractionation regimen of 12Gy delivered in 2Gy fractions BID and
120mg/kg of Cy as an example, one can achieve the threshold lung dose by
reducing the lung dose by 33% or more either through blocking or intensity
modulation. It is also possible to increase fractional dose and reduce the number of
fractions and achieve the same EQD2 for marrow while keeping the lung dose under
the 7.6Gy threshold by delivering fractions once a day and allowing full repair of lung
tissue between fractions. Using an α/β value of 3Gy, lung tissue repair half-life of 4
hours and 33% lung block for all fractions, one can change the fractionation regimen
to only 3 daily fractions of 3.54Gy without sacrificing marrow dose or lung toxicity. A
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similar fractionation scheme of 3 x 3.33Gy has been proposed by Della Volpe et al.40
In their study they found a lethal pulmonary complication (LPC) rate of 3.8% for
patients that receive a MLD of less than 9.4Gy. They suggest keeping the MLD
below 9Gy which is equivalent to 10.8Gy EQD2 in order to keep LPC rate below 5%.
Based on our research, the threshold value of 7.6Gy should prevent IP grade 3 or 4
and it’s easily achievable with lung block or intensity modulation.
6.5

CONCLUSION
Our analysis of 3194 patients that underwent a BMT conditioning regimen

that included many different radiation and chemo regimens, indicates that lung dose
and Cy dose are statistically significant predictors of development of IP.

The

prediction model does not accurately reflect the IP rates of published data,
especially in the high and low range of lung doses. Inconsistent and incomplete
institutional reporting required a lot of assumptions which resulted in vast dispersion
of the data points and resulted in inaccurate prediction model. We were, however,
able to identify a lung dose threshold of 7.6Gy (EQD2) and 120mg/kg of Cy that
should result in negligible IP toxicities of grade 3 or higher. We did not find any
evidence that increase in dose rate would increase IP incidence.
As with all retrospective analyses, these findings may provide guidance in
lung dose constraints or fractionation selection, but they must be validated with
prospective studies.

The fractionation schemes greatly depend on the accurate

knowledge of the α/β ratios and lung tissue repair half-life.

Our predicted lung

threshold dose is based on lung α/β value of 3Gy. This threshold will change if more
current and accurate α/β value for lung becomes available.

The calculations
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presented here also assume incomplete repair model for BID treatments with
fractionations separated by 6 hours and lung tissue repair half time of 4 hours. Care
should be exercised when applying the threshold dose to compute alternative
fractionation regimes.
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CHAPTER 7 “CONCLUSION”
7.1

Summary of findings.
The series of studies presented here represent evaluations of novel treatment

planning optimization and dose calculation algorithms and their applications for
complex sites such as TMI and SBRT. In addition to validating GPU algorithms and
developing structured planning processes for TMI, we evaluated fractionation
schemes and lung toxicity based on historical published data and current
radiobiological models.
The first objective of this research focused on validating the new GPU based
TomoTherapy treatment planning system and its feasibility in extremely large target
volumes.

Using three different target volumes for TMI treatments and several

combinations of machine optimization parameters, we created plans on both CPU
and GPU based systems, keeping the optimization constraints and number of
iterations the same.

We demonstrated that despite the algorithms being

fundamentally different, the difference in plan quality between the systems was very
small. The differences were most likely the result of the gradient descent nature of
the optimization algorithms and fixed number of iterations that may stop the process
at a slightly different solution each time.

Our results are consistent with other

studies36 that validated the GPU based system for smaller target volumes. It was
also shown that the new algorithm is about 20 times faster than the old planning
system. This is a significant improvement since it previously took about 9 – 10 hours
to optimize and calculate TMI plan creating a bottle neck and impeding clinical work
flow.
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In the second aim of this study, discussed in chapter 3, we focused on
comparing the dosimetric and computational results of TomoTherapy’s GPU
planning system with another rotational modality, specifically Eclipse’s VMAT. The
first clear advantage of Tomotherapy’s helical mode of delivery for treatment of TMI
was the ability to create one plan for the entire target volume (target volume being
from head to mid femur). VMAT plan had to be split up into four isocenters and each
sub-plan had to be optimized separately adding complexity and affecting the overall
plan quality. Thanks to the larger aperture, the VMAT plans resulted in much shorter
beam on time, however that benefit was reduced when overall treatment time was
considered due to the need to set up each of the four VMAT sub-plans individually.
We also demonstrated superior plan quality using the GPU system in terms of PTV
hot spots and OAR sparing. However, the inferior plan quality for VMAT plans was
attributed to the software limitations, which precluded the sum of all VMAT arc
degrees from exceeding 1500. With this limitation, most of the voxels in the target
volume were “exposed” to only one arc limiting the solution space available to the
optimizer. With improvements in TPS computing power, this limitation will not be a
factor in the future. While VMAT plans with additional arcs should in theory be able
to achieve plans comparable to those from TomoTherapy’s GPU based system, the
additional arcs will increase overall beam on time, minimizing the advantage of
VMAT’s faster treatment time.

We have also reported overall optimization and

calculation times of 0.9 hours and 3.9 hours for TomoTherapy and Eclipse,
respectively.

The difference in the computational speed comes mainly from

TomoTherapy’s parallel nature of the GPU system.
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The work that followed chapters 2 and 3 represented an attempt to provide
planning and optimization standards aimed at designing a comprehensive planning
guide for TMI.

We have demonstrated the effects of field width, pitch and

modulation factor on relative plan quality. In general, the plan quality improves with
smaller field size, lower pitch or higher modulation factor. However, the gain in
relative plan quality is offset by an increase in beam on time. The most significant
effect on beam on time comes from the selection of the field width. We have also
shown that there is no change in beam on time with change in MF for plans with a
pitch of 0.287 and plans with pitch of 0.43 and MF below 2.0. We developed a plan
quality index “Q” to quantify the relative differences between the plans. This quality
index shows that the relative improvement in plan quality starts to plateau for all
plans reaching a MF of 3 or higher. In other words, increasing MF past 3 will add to
beam on time without much benefit to plan quality improvement. The development
of this planning guide clearly illustrates the limitations of machine optimization
parameters for planning of TMI. This reference is a useful guide for TomoTherapy
users that are currently planning or intend to start TMI treatments. It describes the
effects of user selectable parameters on the treatment plan and can eliminate the
need for exhaustive planning trials in order to improve the plan quality or shorten the
beam on time.
In the next aim of this study we investigated the capability of TomoTherapy’s
GPU based planning system for small and complicated SBRT target volumes. We
planned cases based on the RTOG 0631 protocol and compared the dosimetric
results against other modalities and their respective planning systems.

We
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demonstrated that the GPU based system was able to create plans that met the
dose constraints of RTOG 0631. However, plans created on Cyber Knife and Vero
were able to further reduce dose to OARs in some cases. For CK, this may have
been a result of the use of non-coplanar beams. We have also shown that beam on
time for TomoTherapy equipped with dynamic jaws was on average 6 minutes which
was much faster than all the other modalities except RA FFF. The results in this
chapter show that the new GPU based planning system along with TomoTherapy
equipped with dynamic jaw can create high quality SBRT treatment plans
comparable to or better than other systems and deliver the treatment faster than
most other modalities.
Finally, the last aim evaluated the possibility of utilizing different fractionation
schemes for TMI/TBI treatments without increasing lung toxicities and maintaining
bone marrow target dose.

We have demonstrated that lung EQD2 and Cy are

predictors of IP. The reported data was inconsistent and in some cases incomplete
between the institutions and contributed to dispersion of the data. There was also
limited information on IP rates for high and low range of the lung doses. These
factors, we believe, contributed to the resulting dose response prediction that does
not accurately represent clinical data. However, we were able to identify a dose
threshold from the discrete data points below which no IP cases were reported. This
dose threshold of 7.6Gy (EQD2_repair) was obtained from multi fraction per day
regimens and was based on α/β value of 3Gy and lung tissue repair half-life of 4
hours. Alternative fractionation schemes that may be clinically or logistically more
desirable can be derived from this threshold dose by using EQD2 equation and
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appropriate values of lung tissue fractionation sensitivity and half-life repair time.
This study did not find the dose rate to be related to the development of IP at any
dose levels.
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ABSTRACT
CLINICAL APPLICATIONS OF ADVANCED ROTATIONAL RADIATION
THERAPY
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Purpose: With a fast adoption of emerging technologies, it is critical to fully
test and understand its limits and capabilities.

In this work we investigate new

graphic processing unit (GPU) based treatment planning algorithm and its
applications in helical tomotherapy dose delivery.

We explore the limits of the

system by applying it to challenging clinical cases of total marrow irradiation (TMI)
and stereotactic radiosurgery (SRS). We also analyze the feasibility of alternative
fractionation schemes for total body irradiation (TBI) and TMI based on reported
historical data on lung dose and interstitial pneumonitis (IP) incidence rates.
Methods and Materials: An anthropomorphic phantom was used to create
TMI plans using the new GPU based treatment planning system and the existing
CPU cluster based system.

Optimization parameters were selected based on

clinically used values for field width, modulation factor and pitch. Treatment plans
were also created on Eclipse treatment planning system (Varian Medical Systems
Inc, Palo Alto, CA) using volumetric modulated arc therapy (VMAT) for dose delivery
on IX treatment unit. The constraints ware selected to ensure that at least 95% of
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the PTV received the prescription dose while minimizing the doses to OARs which
consisted of lungs, heart, liver, kidneys, brain, and small bowel.

Resulting plans

were evaluated based on plan quality, optimization and dose calculation times, and
beam on times.

Gamma indices (Γ) were also used to compare planar dose

distributions between the planning systems. In addition a plan quality index (Q) was
developed for quantitative analysis of relative plan quality which included mean and
maximum doses. The GPU planning systems was also evaluated for single fraction
radiosurgery/SBRT capabilities. Treatment plans were created for spine metastases
based on national protocol RTOG 0631 and the dosimetric results were compared to
four other modalities.
A retrospective review was performed of 42 publications that reported IP rates
along with lung dose, fractionation regimen, dose rate and chemotherapy.

The

analysis consisted of nearly thirty two hundred patients and 34 unique radiation
regimens. Multivariate logistic regression was performed to determine parameters
associated with IP and establish does response function.
Results: The results showed very good dosimetric agreement between the
GPU and CPU calculated plans. A gamma analysis Γ(3%, 3 mm) < 1 of the GPU
plan resulted in average of 97% of calculated voxels satisfying Γ < 1 criterion as
compared to baseline CPU plans. The optimization/dose calculation time with the
new GPU system is about 20 times faster than with the CPU system. Is was also
about 4 times faster than Eclipse treatment planning system while achieving superior
OAR dose sparing ranging from 3% to 52%. Analysis of optimization parameters
showed increase in plan quality index (Q) with lower pitch, smaller field size and
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higher modulation factor. The beam on time increases with increasing plan quality
index and associated optimization parameters with the highest effect observed with
field size.
The results from SBRT study show that GPU planning system can maintain
90% target coverage while meeting all the constraints of RTOG 0631 protocol.
Beam on time for Tomotherapy and flattening filter free RapidArc was much faster
than for Vero or Cyberknife.
Retrospective data analysis showed that lung dose and Cyclophosphomide
(Cy) are both predictors of IP in TBI/TMI treatments. The dose rate was not found to
be an independent risk factor for IP. The model failed to establish accurate dose
response function, but the discrete data indicated a radiation dose threshold of
7.6Gy (EQD2_repair) and 120 mg/kg of Cy below which no IP cases were reported.
Conclusion:

The TomoTherapy GPU based dose engine is capable of

calculating TMI treatment plans with plan quality nearly identical to plans calculated
using the traditional CPU/cluster based system, while significantly reducing the time
required for optimization and dose calculation. The new system was able to achieve
more uniform dose distribution throughout the target volume and steeper dose fall
off, resulting in superior OAR sparing when compared to Eclipse treatment planning
system for VMAT delivery. The machine optimization parameters tested for TMI
cases provide a comprehensive overview of the capabilities of the treatment
planning station and associated helical delivery system.

The new system also

proved to be dosimetrically compatible with other leading modalities for treatments of
small and complicated target volumes and was even superior when treatment
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delivery times were compared.

These finding demonstrate that the advanced

treatment planning and delivery system from TomoTherapy is well suitable for
treatments of complicated cases such as TMI and SRS and it’s often dosimetrically
and/or logistically superior to other modalities. The new planning system can easily
meet the constraint of threshold lung dose established in this study. The results
presented here on the capabilities of Tomotherapy and on the identified lung dose
threshold provide an opportunity to explore alternative fractionation schemes without
sacrificing target coverage or lung toxicity.
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